

(72) Glimcher, Laurie H., US

(72) Zhou, Hong, US

(72) Douhan, John, III, US

(73) President and Fellows of Harvard College, US

(51) Int.Cl.⁶ C12N 15/12, C12Q 1/68, G01N 33/554, C07K 14/47, C12Q 1/02

(30) 1994/08/24 (08/295,502) US

(54) **METHODES POUR CARACTERISER DES COMPOSES UTILES
POUR LE TRAITEMENT DES MALADIES AUTO-IMMUNES**

(54) **METHODS OF IDENTIFYING COMPOUNDS USEFUL FOR
TREATING AUTOIMMUNE DISEASES**

(57) La présente invention concerne des procédés d'identification de composés empêchant l'activation de la transcription par le CIITA, et empêchant par conséquent l'expression du gène MHC de classe II. Ce type de composés peut affecter l'induction d'une réaction immunitaire. Ces procédés mettent en oeuvre indépendamment, les domaines d'activation et d'interactions du CIITA. Ces procédés mettent en oeuvre également les domaines d'activation et d'interaction de protéines spécifiques par isotype du CIITA, ce qui permet l'identification de composés qui sont des inhibiteurs de transcription spécifiques par isotype, et qui sont utiles pour intervenir de façon spécifique sur le système immunitaire.

(57) Disclosed are methods of identifying compounds which inhibit transcription activation by CIITA and thus inhibit MHC class II gene expression. Such compounds can affect the induction of an immune response. The methods employ, independently, the activation and interactions domains of CIITA. The methods also employ the activation and interaction domains of isotype-specific CIITA proteins, allowing for the identification of compounds which are isotype-specific inhibitors of transcription and which are useful for selectively affecting the immune system.

SECTION 8 CORRECTION
SEE CERTIFICATE
CORRECTION - ARTICLE 8
VOIR CERTIFICAT





Office de la propriété
intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An Agency of
Industry Canada

*Bureau canadien
des brevets
Certificat de correction*

*Canadian Patent
Office
Certificate of Correction*

Canadian Patent No. 2,197,233
Granted: February 20, 2001

Les corrections suivantes sont faites en
raison de l'article 8 de la *Loi sur les
brevets* et le document doit être lu tel
que corrigé.

The following corrections are made
pursuant to section 8 of the *Patent Act*
and the document should read as
corrected.

In the Patent Grant:

1. The original version of page 42 was removed from the patent.

Agent certification / Certifying Officer

March 7, 2001

Date

Canada

(C.I.P.O. 25)

OPIC  CIPO



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07H 21/04, C07K 14/47, C12N 15/12, C12Q 1/02, 1/68, G01N 33/566	A1	(11) International Publication Number: WO 96/06107 (43) International Publication Date: 29 February 1996 (29.02.96)
(21) International Application Number: PCT/US95/10691 (22) International Filing Date: 22 August 1995 (22.08.95) (30) Priority Data: 08/295,502 24 August 1994 (24.08.94) US (71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). (72) Inventors: GLIMCHER, Laurie, H.; 51 Hampshire Street, W. Newton, MA 02165 (US). ZHOU, Hong; Suite 16, 805 Mt. Auburn Street, Watertown, MA 02172 (US). DOUHAN, John, III; Apartment 7, 233 Commonwealth Avenue, Boston, MA 02116 (US). (74) Agent: FREEMAN, John, W.; Fish & Richardson, P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AU, CA, CN, FI, JP, KR, MX, NO, NZ, PL, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <div style="text-align: center; font-size: 2em; margin-top: 100px;">2197233</div>
(54) Title: METHODS OF IDENTIFYING COMPOUNDS USEFUL FOR TREATING AUTOIMMUNE DISEASES (57) Abstract Disclosed are methods of identifying compounds which inhibit transcription activation by CIITA and thus inhibit MHC class II gene expression. Such compounds can affect the induction of an immune response. The methods employ, independently, the activation and interactions domains of CIITA. The methods also employ the activation and interaction domains of isotype-specific CIITA proteins, allowing for the identification of compounds which are isotype-specific inhibitors of transcription and which are useful for selectively affecting the immune system.		

- 1 -

METHODS OF IDENTIFYING COMPOUNDS USEFUL
FOR TREATING AUTOIMMUNE DISEASES

5

Background of the Invention

This invention relates to autoimmune diseases.

The major histocompatibility (MHC) class II molecules are expressed on the surfaces of antigen-presenting cells and B lymphocytes. By binding antigens and presenting the antigens to T cells, the MHC class II molecules are involved in triggering an immune response. Thus, the level of expression of the MHC class II molecules affects the induction of an immune response.

The genes which encode the α and β polypeptides of the MHC class II antigens are located at the HLA-D (histocompatibility leukocyte antigen-D) region of the chromosome. Isotypes of the class II genes include those which are designated HLA-DR, HLA-DQ, and HLA-DP. Within these genes, there is substantial allelic polymorphism; for example, HLA-DR alleles include DR1, DR2, DR3, and DR4. In addition, subtypes of these alleles exist; for example, subtypes of DR4 include Dw4, Dw10, Dw13, Dw14, and Dw15.

Several autoimmune diseases are associated with expression of particular alleles of the MHC class II genes. Approximately 93% of patients afflicted with rheumatoid arthritis express HLA-DR1, HLA-DR4, or both (McDermott et al., Bulletin on the Rheumatic Diseases, 38:1-10; see Table 1).

- 2 -

Table 1. Population studies of the HLA associations of rheumatoid arthritis				
Population	HLA Antigen	Patients %	Controls %	Relative Risk
White Americans	Dw4	54	16	6
White Americans	DR4	70	28	6
Black Americans	DR4	46	14	5
Japanese	DR4	67	41	3
Mexican	DR4	26	3	11
Asian Indian (in UK)	DR4	17	14	1
	DR1	60	17	7
Israeli Jews	DR1	31	11	4
Israeli Jews	DR4	48	38	1.5
	DR1	16	16	1
Yakima Indians	DR4	41	38	1

Other autoimmune diseases also are linked to expression of particular alleles. For example, Felty's syndrome, Sjögren's syndrome, systemic lupus erythematosus, and the development of toxicities to gold and penicillamine are associated with various HLA-DR alleles (McDermott et al., Bulletin on the Rheumatic Diseases, 38:1-10; see Table 2).

- 3 -

Table 2. HLA associations of syndromes associated with RA, toxicity to penicillamine and gold, and myasthenia gravis

	Syndrome	HLA Antigen	Patients %	Controls %	Relative Risk
5	Felty's syndrome	DR4	96	36	43
	Sjögren's syndrome				
	Primary	B8	59	24	5
		DR3	64	31	4
	Sjögren's syndrome				
	Secondary to RA	DR4	65	31	4
10	Secondary to SLE	DR2	40	24	2
	Side effects to drugs				
	Gold-proteinuria	DR3	79	10 (treated controls)	34
15	Gold-induced hematocytotoxicity	DR3	88	17	36
		B8	88	25	22
	Penicillamine-induced				
	thrombocytopenia	DR4	93	71	5
	myasthenia gravis	DR1	70	18	11
		B35 DR1	50	5	19

As another example, pauciarticular juvenile rheumatoid
 20 arthritis is associated with HLA-DPB2.1 (Begovich et al.,
 1989, PNAS 86:9489-9493). Approximately 70% of patients
 with insulin-dependent diabetes mellitus express HLA-DQ3.2B,

- 4 -

DQA1, or DQB1, and susceptibility to the autoimmune dermatologic disease pemphigus vulgaris is linked to expression of HLA-DQB1.3 (Scharf et al., 1989, PNAS 86:6215-6219).

- 5 Activation of transcription of the MHC Class II genes is dependent upon the transactivator CIITA (Steimle et al., 1993, Cell 75:135-146).

Summary of the Invention

10 We have discovered that a portion of CIITA is sufficient, in the absence of the remainder of the protein and in the presence of an otherwise complete transcription system, to activate transcription. We refer to this domain as the CIITA transcription activation domain, and we have established that it
15 provides useful information for identifying compounds which inhibit CIITA-dependent transcription. Such compounds are potential autoimmune disease therapeutics by virtue of their ability to inhibit transcription of the MHC class II genes. We have also discovered that a
20 second portion of CIITA is sufficient, in the absence of the remainder of the protein and in the presence of an otherwise complete transcription system, to mediate the interaction of CIITA and its target protein in the cellular transcription machinery and to activate all MHC
25 class II promoters. We refer to this domain as the CIITA interaction domain, and compounds which inhibit binding of this domain to its target protein can inhibit CIITA-dependent transcription and thus are potential autoimmune disease therapeutics. We also have discovered that a
30 mutant of CIITA (referred to herein as clone 13 CIITA) activates transcription of a subset of the MHC class II genes. We refer to this mutant as isotype-specific; the transcription activation and interaction domains of isotype-specific CIITA proteins are useful for

- 5 -

identifying compounds which are isotype-specific inhibitors of transcription.

Accordingly, the invention features methods which employ the CIITA activation domain or interaction domain to determine whether a compound is a potential autoimmune disease therapeutic. The presence or absence of a functional CIITA activation domain or a functional CIITA interaction domain can be established using the transcription measuring techniques described below. In one method, the ability of a compound to inhibit transcription of a reporter gene is measured, with inhibition of transcription indicating that the compound is a potential autoimmune disease therapeutic. In another method, the ability of a compound to inhibit binding of the CIITA interaction domain to its target protein is measured, with inhibition of binding indicating that the compound is a potential autoimmune disease therapeutic. In still another method, the ability of the CIITA interaction domain to mediate transcription is measured in the absence of a CIITA transcription activation domain and in the presence of the transcription activation domain of another protein. Compounds which inhibit the function of the interaction domain are potential autoimmune disease therapeutics. By measuring the ability of the wild-type CIITA interaction domain to mediate transcription in the presence of compounds to be tested and by monitoring for the expression of each isotype, this method allows for the identification of compounds which are isotype-specific inhibitors of transcription. In the presence of an isotype-specific inhibitor, the wild-type CIITA interaction domain mediates the transcription of only a subset of MHC class II genes.

The invention further features methods which employ isotype-specific CIITA interaction and

- 6 -

transcription activation domains to identify compounds which are isotype-specific inhibitors of transcription. In these methods compounds are tested for their ability to differentially affect transcription mediated by wild-
5 type and isotype-specific CIITA interaction and transcription activation domains. Such isotype-specific inhibitors are useful for selectively affecting the immune system.

Inhibition of transcription can be measured in
10 vivo, in vitro, or in cell-based assays. A wide variety of techniques for measuring the activity of a transcription activation domain are known in the art (see, e.g., Keegan et al., 1986, Science 23: 699; Ma et al., 1987, Cell 48: 847; Lin et al., 1988, Cell 54: 659;
15 Sadowski et al., 1988, Nature 335: 563; Roberts et al., 1993, Nature 363: 741; and Ma et al., 1988, Cell 55: 443). These and other transcription assays can be modified for the purpose of identifying compounds which inhibit CIITA activation of transcription. This can be
20 accomplished by substituting the newly-identified CIITA transcription activation domain for the activation domain used in a previously described assay. Compounds which inhibit CIITA activation of transcription can be identified by simply adding the compounds to the
25 transcription reaction and determining whether the compound inhibits transcription. Such compounds are potential autoimmune disease therapeutics.

In preferred embodiments, potential autoimmune disease therapeutics are identified by:

- 30 a) providing a fusion protein which includes a CIITA transcription activation domain (without a functional CIITA interaction domain) fused to a DNA binding protein (e.g., the DNA binding/dimerization domain of LexA or the DNA binding domain of GAL4);

- 7 -

b) providing the fusion protein in a transcription system (e.g., *in vitro* or in a prokaryotic or eukaryotic cell such as a bacterial cell, a yeast cell, a plant cell, or a mammalian cell), with the
5 transcription system having DNA which has a regulatory sequence (e.g., on a plasmid or on a chromosome) to which the fusion protein binds, and the regulatory sequence being operably linked to a reporter gene (e.g., a gene encoding β -galactosidase, CAT, GUS, luciferase, human
10 growth hormone, or alkaline phosphatase);

c) measuring the level of transcription of the reporter gene (e.g., by using standard techniques to measure the level or activity of an RNA or protein product of the reporter gene. For example, transcription
15 of the lacZ gene can be measured by growing the cells in or on media containing X-gal, and measuring the amount of blue chromophore produced); and

d) performing steps a-c, above, in the presence of the compound to be tested, a decrease in the level of
20 transcription (relative to levels seen in the absence of the compound) indicating that the compound inhibits CIITA activation of transcription and therefore is a potential autoimmune disease therapeutic.

In other preferred embodiments, the CIITA
25 interaction domain is used to identify potential autoimmune disease therapeutics. These methods involve:

a) providing a fusion protein which includes a CIITA interaction domain fused to a transcription activation domain other than that of CIITA (e.g., the
30 transcription activation domain of Herpes Simplex Virus α -transducing factor (α -TDF));

b) providing a CIITA-interacting target protein (e.g., the CIITA-interacting target protein of a human B cell);

- 8 -

c) providing the fusion protein and the target protein in a transcription system (e.g., in vitro or in a prokaryotic or eukaryotic cell such as a bacterial cell, a yeast cell, a plant cell, or a mammalian cell such as a human B cell (e.g., clone 13, Raji, or RM3 cells)), with the transcription system having DNA which has a regulatory sequence including an MHC class II promoter sequence (e.g., on a plasmid or on a chromosome), and the regulatory sequence being operably linked to a reporter gene (e.g., an MHC class II gene, a gene encoding β -galactosidase, CAT, GUS, luciferase, human growth hormone, or alkaline phosphatase); and

d) measuring the level of transcription of the reporter gene (e.g., by using standard techniques to measure the level or activity of an RNA or protein product of the reporter gene. For example, transcription of the MHC class II genes can be measured in a human B cell line by using FACS to assay an increase in expression of the MHC class II molecules on the cell surface.); and

e) performing steps a-d, above, in the presence of the compound to be tested, a decrease in the level of transcription (relative to levels seen in the absence of the compound) indicating that the compound inhibits the ability of the CIITA interaction domain to mediate transcription and therefore is a potential autoimmune disease therapeutic. Compounds which are isotype-specific inhibitors of transcription can be identified by virtue of their ability to differentially inhibit expression of the MHC class II genes. For example, expression of the wild-type CIITA interaction domain clone 13 cells restores transcription of the HLA-DR, -DQ, and -DP isotypes. A compound which inhibits transcription, but not in an isotype-specific manner, will prevent restoration of expression of all 3 genes.

2197233

- 9 -

In contrast, an isotype-specific inhibitor of transcription will interfere with restoration of expression of only a subset of the genes.

In other preferred embodiments, compounds which
5 are potential autoimmune disease therapeutics are identified by:

a) providing a first fusion protein which includes a CIITA interaction domain (without a functional CIITA activation domain) fused to a DNA binding protein (e.g.,
10 the DNA binding/dimerization domain of LexA, or the DNA binding domain of GAL4);

b) providing the fusion protein in a transcription system (e.g., *in vitro* or in a prokaryotic or eukaryotic cell such as a bacterial cell, a yeast
15 cell, a plant cell, or a mammalian cell), with the transcription system having DNA which has a regulatory sequence (e.g., on a plasmid or on a chromosome) to which the first fusion protein binds, and the regulatory sequence being operably linked to a reporter gene (e.g.,
20 a gene encoding β -galactosidase, CAT, GUS, luciferase, human growth hormone, or alkaline phosphatase);

c) providing a second fusion protein, the second fusion protein being characterized in that it includes a transcription activation domain (e.g., the transcription
25 activation domain of B42) fused to a CIITA-interacting target protein as defined herein;

d) measuring the level of transcription of the reporter gene (e.g., by using standard techniques to measure the level or activity of an RNA or protein
30 product of the reporter gene. For example, transcription of the lacZ gene can be measured by growing the cells in or on media containing X-gal, and measuring the amount of blue chromophore produced); and

e) performing steps a-d, above, in the presence
35 of the compound to be tested, a decrease in the level of

- 10 -

transcription (relative to levels seen in the absence of the compound) indicating that the compound inhibits the ability of the CIITA interaction domain to bind its target protein and therefore is a potential autoimmune disease therapeutic. The compound which inhibits binding may function by a variety of methods including sterically interfering with binding or altering the structure of CIITA or its target protein. Although the exact mechanism by which the compound abolishes transcription may be unknown, the compound nevertheless is valuable as a therapeutic. Other methods of measuring protein-protein interactions can also be used to identify compounds which inhibit binding of the CIITA interaction domain to its target protein. Using standard molecular biology techniques, one skilled in the art can employ ELISAs, Southwestern blotting, filter- and membrane-bound proteins, or immobilized proteins to identify compounds which inhibit binding of the CIITA interaction domain to its target protein.

20 The invention also features a substantially purified polypeptide which includes a CIITA transcription activation domain without a functional CIITA interaction domain. Preferably, the polypeptide includes a greater than 50 amino acid sequence substantially identical to a greater than 50 amino acid sequence of amino acids 26-352 of the sequence shown in Fig. 1.

In a related aspect, the invention features substantially pure DNA (e.g., genomic DNA, cDNA, or synthetic DNA) encoding a CIITA transcription activation domain without encoding a functional CIITA interaction domain.

The invention further features a substantially purified polypeptide which includes a CIITA interaction domain without including a functional CIITA transcription activation domain. Preferably, the polypeptide includes

- 11 -

a greater than 50 amino acid sequence substantially identical to a greater than 50 amino acid sequence of amino acids 301-1130 of the sequence shown in Fig. 1.

In a related aspect, the invention features
5 substantially pure DNA (e.g., genomic DNA, cDNA, or synthetic DNA) encoding a CIITA interaction domain without encoding a functional CIITA transcription activation domain.

In addition, the invention features a
10 substantially purified polypeptide which includes the interaction domain of the CIITA polypeptide of the clone 13 cell line (for a description of the cell line, see Ono et al., 1991, J. Exp. Med. 173:629-637). The clone 13 CIITA activates transcription of the MHC class II DQ gene
15 but does not activate transcription of the MHC class II DR and DP genes. Preferably, the polypeptide includes a greater than 50 amino acid sequence substantially identical to a greater than 50 amino acids 301-1077 of the sequence shown in Fig. 1, while lacking amino acids
20 1-300 and 1078-1130 of the sequence shown in Fig. 1. In a related aspect, the invention includes a substantially pure DNA (e.g., genomic DNA, cDNA, or synthetic DNA) encoding the clone 13 CIITA.

Other isotype-specific CIITA mutants also are
25 included in the invention, and the invention further features methods which employ the activation and interaction domains of isotype-specific mutants of CIITA to determine whether a compound is an isotype-specific inhibitor of transcription. A compound which is an
30 isotype-specific inhibitors also is a potential autoimmune disease therapeutic. Such a compound is particularly useful as it can inhibit the transcription of particular genes known to be involved in autoimmune diseases while allowing expression of other MHC class II
35 genes. Thus, an isotype-specific compound, when used as

- 12 -

an autoimmune disease therapeutic, can avoid causing generalized immunosuppression.

A compound which is isotype-specific can be identified by using an isotype-specific CIITA in one of the inhibition assays described herein, and comparing the results with those obtained using wild-type CIITA or a CIITA mutant of a different isotype specificity. For example, a compound which inhibits transcription that is dependent upon wild-type CIITA, but not the clone 13 CIITA, is useful for inhibiting transcription of the MHC class II DR and DP genes. Because expression of DR1 and/or DR4 is associated with 93% of rheumatoid arthritis cases, a compound which specifically inhibits transcription of the DR genes is a strong candidate for a rheumatoid arthritis therapeutic.

Similarly, two isotype-specific mutants of CIITA can be used to determine whether a compound is an isotype-specific inhibitor of transcription. For example, a comparative method can involve a first CIITA mutant which activates transcription of DR and DP, and a second CIITA mutant which activates transcription of only DP. A compound which inhibits the ability of the first mutant but not the second mutant is useful for selectively inhibiting the expression of DR.

By "class II transactivator gene" (CIITA gene) is meant a gene encoding an activator of transcription, with the gene having about 80% or greater sequence identity to the CIITA sequence of Fig. 1 (SEQ ID NO: 1).

By "CIITA transcription activation domain" is meant a polypeptide having about 80% or greater sequence identity to amino acids 26-352 of the CIITA polypeptide shown in Fig. 1 without having a functional CIITA interaction domain.

By "CIITA interaction domain" is meant a polypeptide having about 80% or greater sequence identity

- 13 -

to amino acids 301-1130 of the CIITA polypeptide shown in Fig. 1 without having a functional CIITA transcription activation domain. An example of a mutant CIITA interaction domain is the interaction domain of clone 13 CIITA, the DNA sequence of which is characterized, at least in part, by a deletion of nucleotides 3211-3214 of the wild-type CIITA sequence shown in Fig. 1 (this corresponds to nucleotides 3326-3329 of the cDNA sequence described previously (Steimle et al., *infra*)), resulting in a protein which is truncated by 53 amino acids relative to wild-type.

It will be understood that the CIITA transcription activation and interaction domains as defined herein overlap by about 51 amino acids. However, the region of overlap is not sufficient to constitute a functional transcription activation or interaction domain. Thus, a polypeptide having amino acids 26-352 and lacking amino acids 353-1130 of the sequence shown in Fig. 1 has a functional transcription activation domain but lacks a functional interaction domain. Similarly, a polypeptide having amino acids 301-1130 and lacking amino acids 1-300 of the sequence shown in Fig. 1 has a functional interaction domain, but lacks a functional transcription activation domain.

By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation).

By "operably linked" is meant that a gene and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

By "reporter gene" is meant a gene whose expression may be assayed; such genes include, without

- 14 -

limitation, the lacZ, chloramphenicol acetyltransferase (CAT), β -glucuronidase (GUS), and luciferase genes.

By "substantially identical" is meant a polypeptide or nucleic acid exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably at least 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, substitutions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

By "substantially pure polypeptide" is meant a polypeptide which has been separated from components which naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more

- 15 -

preferably at least 90%, and most preferably at least 99%, by weight, the desired protein. A substantially pure CIITA transcription activation domain or CIITA interaction domain can be obtained, for example, by
5 extraction from a natural source (e.g., a human cell); by expression of a recombinant nucleic acid encoding a CIITA transcription activation domain or CIITA interaction domain; or by chemically synthesizing the polypeptide. Purity can be measured by any appropriate method (e.g.,
10 column chromatography, polyacrylamide gel electrophoresis, and HPLC analysis).

A protein is substantially free of naturally associated components when it is separated from those contaminants which accompany it in its natural state.
15 Thus, a protein which is chemically synthesized, synthesized *in vitro*, or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure
20 polypeptides include those derived from eukaryotic organisms but synthesized in *E. coli* or other prokaryotes.

By "substantially pure DNA" is meant DNA that is free of the genes which, in the naturally-occurring
25 genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of
30 a prokaryote or eukaryote (e.g., a yeast cell); or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a
35 hybrid gene encoding additional polypeptide sequence.

- 16 -

Detailed Description

The drawings will first be described.

Fig. 1 is a listing of the nucleotide and predicted amino acid sequences of full length CIITA (SEQ ID NO: 1).

Fig. 2 is a schematic representation of the CIITA deletion mutants and the *in vivo* assay used to identify the CIITA transcription activation and interaction domains. The results of the transcription assays are also summarized in this Fig.

Fig. 3 is a photograph of the yeast cells used in the transcription assays to identify the CIITA transcription activation and interaction domains.

Fig. 4 is a histogram showing data obtained from a colorimetric assay used to measure transcription of the lacZ gene for identification of the CIITA transcription activation and interaction domains.

Fig. 5 is a schematic representation of plasmid pCMV.ciita.

Fig. 6A-E is a series of FACS profiles which shows that expression an α -TDF/CIITA fusion protein in clone 13 and RM3 cells restores expression of the MHC class II genes.

Fig. 7 is a series of FACS profiles which shows that expression of wild-type CIITA in clone 13 cells corrects the deficiency in the expression of the DR and DP isotypes and increases expression of DQ.

Fig. 8A-F is a schematic representation of plasmids described herein.

- 17 -

The CIITA Transcription Activation Domain

We have identified, for the first time, a segment of CIITA that is sufficient, in the absence of the remainder of the CIITA protein and in the presence of an otherwise complete transcription system, to activate transcription. We refer to this segment as the transcription activation domain of CIITA. To identify this domain of CIITA, a series of plasmids was constructed (from the vector pEG202) to produce fusion proteins containing portions of CIITA attached to the N-terminal 202 amino acid dimerization and DNA binding domain of the *E. coli* repressor protein LexA. Methods for constructing these plasmids and other plasmids described herein are provided below under "Construction of Plasmids."

Yeast cells of the strain EGY48 (*his3⁻* and *ura3⁻*) then were co-transformed with each LexA-CIITA construct, independently, and a *lacZ* reporter plasmid (pSH18-34). Expression of these plasmids in yeast was maintained by expression of the *HIS3* gene from the LexA-CIITA plasmid, and expression of *URA3* from pSH18-34. The regulatory sequences of the *lacZ* reporter plasmid included 8 LexA binding sites in place of the *GAL1* upstream activating sequences (Fig. 2). In this assay, the LexA polypeptide served as a DNA-binding protein, bringing the CIITA polypeptides close to the site of transcription.

In the absence of a LexA fusion protein, yeast bearing the pSH18-34 reporter gene did not produce detectable quantities of β -galactosidase from the *lacZ* gene and appeared white on X-gal-containing media (Fig. 3; pHRFM1, a negative control). In addition, yeast bearing a plasmid expressing only the LexA N-terminal 202 amino acids or a fusion protein which is known not that transcriptional activity (pSH17-4) failed to produce detectable quantities of β -galactosidase. In contrast,

- 18 -

yeast strains having the LexA polypeptide fused to the transcription activation domain of CIITA (approximately the N-terminal 29%) induced synthesis of sufficient amounts of β -galactosidase that the host yeast cells
5 appeared blue on X-gal-containing media (Fig. 3; pSH17-4, a positive control). In addition, quantitative colorimetric assays were performed by measuring the optical density of media containing the fusion proteins and o-nitrophenyl- β -galactoside (ONPG) (see Fig. 4)
10 (Ausubel et al., In: Current Protocols in Molecular Biology, J. Wiley & Sons, 1994). Our data also indicate that a polypeptide which includes approximately 8% of the N-terminal region of CIITA is sufficient to activate transcription. This portion of CIITA contains the acidic
15 portion of the transcription activation domain; if desired, the experiments performed with the N-terminal 29% can be compared with experiments performed with the N-terminal 8%. A polypeptide which includes approximately 29% of the N-terminal region of CIITA
20 activates transcription at least as efficiently as the full length CIITA protein does. Thus, amino acids 26-352 and nucleotides 78 to 1,056 of the full length CIITA (see Fig. 1) represent the transcription activation domain (these numbers refer to the CIITA coding sequence, the
25 beginning of which is at nucleotide 116 of the CIITA cDNA sequence (Steimle et al., *infra*)).

Use of the CIITA Transcription Activation Domain to
Identify Autoimmune Disease Therapeutics

The activation domain of CIITA can be used in a
30 method of identifying compounds which inhibit CIITA-dependent transcription. Because CIITA is required for activation of MHC class II genes, compounds which specifically inhibit CIITA-dependent transcription are strong candidates for autoimmune disease therapeutics.
35 Our discovery that a segment of CIITA (termed the CIITA

- 19 -

transcription activation domain) is able to activate transcription in the absence of the remainder of the CIITA protein, and in the presence of an otherwise complete transcription system, facilitates the
5 identification of compounds which inhibit transcription activation by CIITA.

Useful compounds are identified by their ability to inhibit CIITA-dependent transcription. To this end, the compound can be tested for inhibition of
10 transcription in any transcription assay system which employs the CIITA activation domain. There now follows an example of an assay which can be used to identify compounds which inhibit CIITA-dependent transcription; compounds identified with this assay are candidates for
15 autoimmune disease therapeutics. Other assays (e.g., those described by Keegan et al., 1986, Science 23: 699; Ma et al., 1987, Cell 48: 847; Lin et al., 1988, Cell 54: 659; Sadowski et al., 1988, Nature 335: 563; Roberts et al., 1993, Nature 363: 741; and Ma et al., 1988, Cell 55:
20 443) can be modified to employ the CIITA transcription activation domain which we have discovered. The CIITA transcription activation domain can simply be cloned into the appropriate vector, and thus other transcription assays are not excluded from this invention, the metes
25 and bounds of which are determined by the claims below.

Example 1: Identification of Compounds which Inhibit the CIITA Transcription Activation Domain

To identify useful compounds, the host yeast strain EGY48 (his3⁻, ura3⁻, and leu⁻) is transformed with
30 two plasmids. The first plasmid, pSH18-34, carries the GAL1 TATA transcription start site and a segment of the GAL1 coding sequence operably linked to the lacZ gene (Zervos et al., 1993, Cell 72: 223-232 and Gyuris et al., 1993, Cell 75: 791-803). This plasmid also carries 8
35 binding sites for LexA in place of the GAL1 upstream

- 20 -

activating sequences, and it carries a URA3 selectable marker. The second plasmid, pEG.ciita.N29, is derived from the parental plasmid pEG202 and carries sequences which encode the CIITA transcription activation domain.

5 This plasmid also carries a gene for a selectable marker (HIS3) and the DNA-binding and dimerization domains of LexA (amino acids 1-202). In control yeast strains, the second plasmid can be pSH17-4 (Gyuris et al., 1993, Cell 75:791-803) which encodes LexA fused to a transcription

10 activation domain such as those of pHRFM1 or CDK2 (Zervos et al., 1993, Cell 72: 223-232 and Gyuris et al., 1993, Cell 75: 791-803).

Small cultures of the doubly-transformed yeast strains are mixed with the compounds to be screened and

15 grown in a suitable medium (e.g., SGR, -his, -ura, + X-gal (80 mg/L)) under suitable conditions (e.g., at 30° C with agitation overnight). The amount of blue chromophore produced is then determined (e.g., by measuring the optical density or by manually examining

20 the cultures). Compounds which inhibit activation of transcription by the test plasmid (pEG.ciita.N29) but not the control plasmid (pSH17-4) can inhibit expression of the MHC class II molecules, and, therefore, are strong candidates for autoimmune disease therapeutics.

25 The CIITA Interaction Domain

The deletion analysis described above also indicated that a polypeptide which included amino acids 1-26 and 301-1130 (nucleotides 1-78 and 903-3390) of the full-length CIITA did not, alone, activate transcription

30 (Figs. 1, 2, and 3). Since this domain is not capable of activating transcription in the absence of a transcription activation domain (derived from CIITA or another activator of transcription), we conclude that this domain mediates transcription by binding to another

35 component of the cellular transcription machinery (e.g.,

- 21 -

a polymerase or a DNA binding protein). Accordingly, amino acids 301-1130 (the C-terminal 74%) of CIITA have been termed the CIITA interaction domain. Although the CIITA interaction domain cannot, alone, activate

transcription, compounds which inhibit binding of the interaction domain to its normal cellular target protein are useful for inhibiting transcription of CIITA and therefore are potential autoimmune disease therapeutics. Use of the CIITA Interaction Domain to Restore MHC Class

II Gene Expression

To confirm that amino acids 301-1130 encompass the CIITA interaction domain, we assayed the ability of this region of CIITA to restore MHC class II gene expression in mutant cell lines which fail to express those genes.

In these studies, we used the plasmid pCMV.ciita (Fig. 5) to construct a plasmid, pCMV. α TDF-CIITA.C70 which creates a fusion protein between the interaction domain of CIITA and the transcription activation domain of α -transducing factor of Herpes Simplex Virus (HSV) strain F. As a negative control, a plasmid, pCMV.CIITA.C74, was created in which the CIITA transcription activation domain was deleted. For a second negative control, pCMV.ciita Δ HindIII, which encodes the CIITA transcription activation domain in the absence of an interaction domain, was used. As a control for transfection efficiency, cell were transfected with pCMV/K^b. As a positive control, the cells were transfected with pCMV.ciita which encodes the full-length CIITA. These plasmids were transfected, independently, into human B cells. One B cell line, RM3, is deficient in expression of the DR, DP, and DQ isotypes. A second B cell line, clone 13, is deficient in expression of DR and DP, but not DQ. The third cell line, Raji, expresses wild-type levels of the three MHC class II genes. Cells from each line were stained, using standard techniques, with

- 22 -

antibodies against DR (LB3.1), DQ (SPV.L3, which are equivalent to Genox.53), DP (B7/21), class I molecules (W6/32) or K^b (Y-3) and then analyzed by fluorescence activated cell sorting (FACS; Fig. 6). These data indicate that expression of the α -TDF/CIITA interaction domain fusion protein in mammalian B cells restores expression of the MHC class II genes on the surface of the mutant cell lines. Thus, amino acids 301-1130 of CIITA can function as an interaction domain.

10 Example 2: Cell-based Assay of Compounds Which Are Interaction Domain Inhibitors

The above-described method can be modified to provide a method of determining whether a compound inhibits CIITA-dependent transcription. In this method, 15 a compound to be tested is simply added to the culture of transfected cells. A compound which inhibits the ability of the α -TDF/CIITA fusion protein to restore expression of the MHC class II molecules on the cell surface is a potential autoimmune disease therapeutic. This method 20 also permits the identification of compounds which are isotype-specific inhibitors of transcription. For example, a compound which causes the α -TDF/CIITA fusion protein to restore expression of only a subset of the MHC class II genes is an isotype-specific inhibitor. Such a 25 compound is particularly valuable as a potential autoimmune disease therapeutic because it allows for selective inhibition of MHC class II gene transcription. The cell-based assay described above can be used alone or in conjunction with the assay described below which 30 employs two fusion proteins.

- 23 -

The CIITA-Interacting Target Protein

In other assays, a compound which inhibits CIITA-dependent transcription can also be identified by virtue of its ability to inhibit binding of the CIITA interaction domain to its target protein in the cellular transcription machinery. Now that we have discovered that the function of amino acids 301-1130 of CIITA is to mediate transcription by binding to another protein(s) (referred to herein as the target protein(s)) in the cell, the CIITA target protein can be cloned rapidly and conveniently by employing the widely-used technique known as interaction trap cloning. As described below, a modification of interaction trap cloning can be used to identify compounds which inhibit binding of the CIITA interaction domain to its target protein; such compounds are potential autoimmune disease therapeutics. Briefly, interaction trap cloning employs the interaction domain of a protein and the activation domain of a second protein to rapidly and easily identify a target protein with which the interaction domain associates. The target protein enables the interaction domain to mediate transcription of a reporter gene; transcription can be assayed as described infra. Using this system, and the CIITA interaction domain which we have discovered, the target protein of the CIITA interaction domain can be cloned rapidly and easily. There now follows a description of cloning the CIITA target protein and the use of the CIITA interaction domain to identify potential autoimmune disease therapeutics.

30 Example 3: Cloning the CIITA-Interacting Target Protein

To clone the target protein of the CIITA interaction domain, a host cell (e.g., a yeast cell of the strain EGY48) is transformed with a first plasmid which encodes a first fusion protein. The first fusion protein includes a DNA binding protein (e.g., the N-

- 24 -

terminal 202 amino acids of LexA) fused to the CIITA interaction domain without a CIITA activation domain. The yeast cell also carries a reporter gene (e.g., a lacZ, CAT, GUS, human growth hormone, alkaline phosphatase, or luciferase gene) which is operably linked to a regulatory sequence to which the first fusion protein binds. The reporter gene can be located on a plasmid or a chromosome. In addition, the yeast cell is transformed with a plasmid which encodes a second fusion protein. The second fusion protein includes the transcription activation domain of a protein (e.g., the B42 acidic activation domain (Ma et al., 1988, Cell 55:443-446)) fused to a test polypeptide which is assayed for its ability to mediate transcription of the reporter gene as described infra. The polypeptide which permits transcription of the reporter gene is the target protein of the CIITA interaction domain. DNA molecules encoding the potential target protein are obtained from a library (such as a cDNA library prepared from poly-A⁺ RNA obtained from the human Burkitt's B cell lymphoma, Raji). In control assays, the CIITA interaction domain is replaced by the interaction domain of another protein (e.g., pHRFM1 or CDK2 (Zervos and Gyuris, infra)).

Example 4: Use of the CIITA Interaction Domain to Identify Autoimmune Disease Therapeutics

Compounds which inhibit transcription by interfering with the CIITA interaction domain can be identified by assaying the compound's ability to inhibit binding of the CIITA interaction domain to its target protein. Any method which measures protein-protein interactions can be used to identify compounds which, when added to the assay, inhibit the protein-protein interaction. For example, assays based on ELISAs, Southwestern blotting, filter- and membrane-bound proteins, and immobilized proteins are among the assays

- 25 -

which can be used to measure inhibition of binding of the CIITA interaction domain to its target protein. There now follows a detailed example of a method for identifying compounds which inhibit the function of the
5 CIITA interaction domain, and which, therefore, are potential autoimmune disease therapeutics.

In one preferred method, a host cell (e.g., a yeast cell of the strain EGY48) is transformed with a first plasmid which encodes a first fusion protein. The
10 first fusion protein includes a DNA-binding protein (e.g., the N-terminal 202 amino acids of LexA) fused to the CIITA interaction domain without a CIITA activation domain. The yeast cell also carries a reporter gene (e.g., a lacZ, CAT, GUS, human growth hormone, alkaline
15 phosphatase, or luciferase gene) which is operably linked to a regulatory sequence to which the fusion protein binds. The reporter gene can be located on a plasmid or a chromosome. In addition, the yeast cell is transformed with a plasmid which encodes a second fusion protein.
20 The second fusion protein includes the transcription activation domain of a protein (e.g., B42) fused to the target protein of the CIITA interaction domain.

Useful compounds are identified by their ability to inhibit transcription of the reporter gene in this
25 assay. Small cultures of the transformed cells are mixed with the compounds to be tested and grown in a medium which is suitable to maintain expression of the plasmids, and under suitable conditions (e.g., at 30° C with agitation overnight). The level of gene expression
30 is then measured. For example, if the lacZ gene is used as the reporter gene, the amount of blue chromophore produced in the presence of X-gal can be determined (e.g., by measuring the optical density or by manually examining the color of the cell cultures). Compounds
35 which inhibit activation of transcription in assays

- 26 -

employing the CIITA interaction domain but not the control interaction domain can inhibit expression of the MHC class II molecules, and, therefore, are strong candidates for autoimmune disease therapeutics. This
5 assay can be used alone or in combination with the cell-based assay described in Example 2.

Identification of The CIITA Clone 13 Mutant

We have identified a mutation in CIITA which alters the protein's ability to activate transcription of
10 certain MHC class II isotypes. This mutant CIITA, termed clone 13 CIITA, is present in the clone 13 cell line, a derivative of the human B cell lymphoma, Jijoye (available from L. Glimcher, Harvard University, MA). The clone 13 CIITA is defective in transcription of the
15 DR and DP isotypes but not the DQ isotype of the MHC class II genes. We have discovered that expression of the wild-type CIITA gene in clone 13 cells enables the cells to transcribe the DR and DP isotypes. In these studies, the CIITA gene was cloned into the vector pCMV,
20 and the resulting vector, pCMV.ciita (Fig. 5), was then transfected by electroporation into clone 13 cells.

The transfected cells were analyzed by FACS for expression of the DR and DP isotypes (Fig. 7). As controls, Raji cells (which express the DR, DP, and DQ
25 isotypes) and the untransformed clone 13 cells were examined in the same manner. Standard techniques were used to stain the cells with antibodies. In addition to staining the cells with anti-DR (LB3.1; L243 antibodies from Becton-Dickinson can also be used), anti-DQ
30 (Genox.53; ATCC #HB103), or anti-DP (B7/21; Becton-Dickinson) antibodies, the cells were stained with anti-class I antibodies (W6/32; a positive control, ATCC #HB95) and anti-Kb antibodies (Y-3; a negative control, ATCC #HB176). Referring to Fig. 7, expression of CIITA
35 in clone 13 cells increases the relative fluorescence of

- 27 -

those cells when they are stained with anti-DP, anti-DR, or anti-DQ antibodies. Thus, expression of wild-type CIITA in clone 13 cells corrects the deficiency of the clone 13 mutant CIITA.

5 Example 5: Identification of Isotype-Specific Compounds

The interaction domain of the clone 13 mutant CIITA can be used in the assays described in Example 4 to identify compounds which are isotype-specific inhibitors of CIITA-dependent transcription. If desired, the clone
10 13 CIITA transcription activation domain or full-length polypeptide can be used in other assays to identify useful compounds. Compounds which inhibit CIITA-dependent transcription involving wild-type CIITA, but not the clone 13 mutant CIITA, are useful for inhibiting
15 expression of the DR and DP MHC class II isotypes without inhibiting expression of the DQ isotype. Such compounds are isotype-specific and can be used to inhibit the expression of particular genes involved in the induction of an immune response, without causing generalized
20 immunosuppression. Because numerous autoimmune diseases, such as rheumatoid arthritis (see Tables 1 and 2) are associated with particular isotypes, compounds which can inhibit expression of a subset of the MHC class II genes are particularly valuable for selectively affecting the
25 immune system.

Other Embodiments

Other embodiments are within the following claims. For example, the activation and interaction domains of isotype-specific CIITA mutants other than the clone 13
30 CIITA are within the invention. Isotype-specific CIITA mutants can be identified as described above for the clone 13 CIITA. Cell lines which are defective in expression of a subset of the MHC class II genes are candidate sources of isotype-specific CIITA proteins. A
35 cell line containing an isotype-specific CIITA can be

- 28 -

identified by expressing wild-type CIITA in the candidate cell line and determining whether expression of CIITA corrects the deficiency in expression of the MHC class II gene(s). The mutant CIITA gene can be cloned using the techniques described for the clone 13 CIITA. Thus, the methods presented in Example 5 are useful for isolating other isotype-specific CIITA mutants which can be used to determine whether a compound is an isotype-specific inhibitors of transcription.

Additional methods of assaying CIITA-dependent transcription also are within the invention. For example, previously-described transcription assays (see, e.g., Keegan et al., 1986, Science 23: 699; Ma et al., 1987, Cell 48: 847; Lin et al., 1988, Cell 54: 659; Sadowski et al., 1988, Nature 335: 563; Roberts et al., 1993, Nature 363: 741; and Ma et al., 1988, Cell 55: 443) can, with appropriate substitution of the CIITA transcription activation domain, be used for identifying useful compounds, by simply adding the compounds to the assay. In addition, modifications of the above-described assay can be used in the invention. For example, other DNA-binding proteins, such as GAL4, can be used in place of LexA. Reporter genes, such as chloramphenicol acetyl transferase (CAT), luciferase, β -glucuronidase (GUS), human growth hormone, alkaline phosphatase or any gene whose expression can be assayed can substitute for the lacZ gene. Host cells other than yeast also can be used; for example, prokaryotic and other eukaryotic cells (e.g., bacterial, mammalian and plant cells) are useful. Methods of measuring protein-protein interactions, such as assays based on ELISAs, Southwestern blotting, filter- and membrane-bound proteins, and immobilized proteins also can be used to identify compounds which inhibit binding of the CIITA interaction domain to its target protein. It will be readily apparent that standard

- 29 -

techniques of molecular biology will enable one to use the CIITA interaction domain in other assays of protein-protein interactions.

Construction of Plasmids

5 The original CIITA templates were obtained by RT-PCR with polyA⁺ RNA extracted from the HLA class II positive B lymphoid cell line Raji. The PCR products were then directly cloned into pCRII (Invitrogen). Of the clones obtained, three (pCRII.ciita.b, pCRII.ciita.h,
10 and pCRII.ciita.p) were used to generate a complete cDNA eukaryotic expression construct (See Figs. 5 and 8).

pCRII.ciita.b: The CIITA-specific PCR primers used for this construct were 5'-GGAAGCTGAGGGCACGAGGAG-3' for the 5' end and 3'-CAGAAGAGACAGGGGACGGTAAC-5' for the
15 3' end.

pCRII.ciita.h: The CIITA-specific PCR primers used for this construct were 5'-CTCCAACAAGCTTCCAAAATG-3' for the 5' end and 3'-GTACAAGAGACTCCTGTGATTG-5' for the 3' end.

20 **pCRII.ciita.p:** The CIITA-specific PCR primers used for this construct were 5'-GTCCCTGAAGGATGTGGAAGAC-3' for the 5' end and 3'-GTCTGACCTTCGTGTCGAAG-5' for the 3' end.

pcMV.ciita: This construct was made via multistep
25 subcloning using pLB-1 as the vector and pCRII.ciita.b, pCRII.ciita.h and pCRII.ciita.p as inserts. First, the vector DNA was prepared by cutting pLB-1 with *Hind*III, treating with T4 polymerase, followed by *Not*I activation digestion; the 5' CIITA DNA insert was prepared by
30 cutting pCRII.ciita.b with *Eco*RI at sites which flank the PCR insert in pCRII constructs, gel purification of the smaller fragment, T4 polymerase treatment, followed by *Not*I activation digestion (*Not*I at nucleotide 1340 in the CIITA sequence). These two fragments were ligated with

- 30 -

T4 ligase and the resulting pCMV.ciita sub-construct is termed pCMV.ciita.b.

pCMV.ciita.b was then digested with *Bam*HI, and the smaller fragment was gel-purified, blunted T4 polymerase, and activated by *Not*I digestion; pCIII.ciita.p was similarly cut with *Eco*RI, blunted with T4 polymerase, and followed by *Not*I activation digestion. The smaller fragment was gel-purified and used. The vector and insert fragments were ligated with T4 ligase, and the resulting pCMV.ciita second sub-construct was termed pCMV.ciita.bp.

pCMV.ciita.bp was further digested with *Bam*HI and *Not*I; pCIII.ciita.h was also cut with *Bam*HI and *Not*I, and the smaller fragment was gel-purified. These two fragments were ligated with T4 ligase and the resulting construct which contains CIITA cDNA sequences (nucleotides 48-4471) is termed pCMV.ciita.bp.

pCMV.CIITA: This construct was made after pCMV.ciita had been constructed and confirmation of its biological function in restoring HLA class II general expression (by transfection of HLA class II-negative cell lines (RM3 and clone 13) and FACS analysis). The CIITA cDNA construct termed pKS/CIITA (+) (from Dr. B. Mach, University of Geneva; Geneva, Switzerland) was also used in these experiments. In this plasmid, the vector was pBluescript™ KS(+) (Stratagene), and the cDNA was inserted into the *Sal*I site of the multiple cloning site. To make pCMV.CIITA, pCMV was digested with *Xho*I and *Nhe*I, and the CIITA cDNA fragment was obtained by cutting pKS/CIITA with *Xho*I and *Spe*I whose recognition sites flank the cDNA insert. The two fragments were ligated with T4 ligase, and the resulting construct was termed pCMV.CIITA (the upper-case letters indicate that the DNA source was from original cDNA library).

- 31 -

PEG.CIITA: This plasmid was made using pEG.CIITA.SalI and pTrc.CIITA. pEG.CIITA.SalI was digested with BamHI and the larger fragment was gel-purified; the CIITA sequence was obtained by digesting 5 pTrc.ciita with BamHI, and the vector and insert were ligated with T4 ligase.

pEG.CIITA.SalI pEG202 was first linearized with SalI and dephosphorylated with CIP; CIITA cDNA was obtained by SalI digestion of pCMV.CIITA; the vector and 10 insert fragment were then ligated and the resulting intermediate pEG construct with the CIITA cDNA insert was termed pEG.CIITA.SalI.

pTrc.ciita This construct was originally generated from over-expression of the recombinant CIITA 15 protein. First the 5' CIITA sequence was cloned (using PCR, in the same way as in the construction of pEG.ciita.N29, below) into the BamHI site and the XhoI site of pTrcHis C (Invitrogen). The resulting plasmid, termed pTrc5 or pTrc/ciita5, was linearized with XhoI, 20 blunted with T4 polymerase, and activated with DraIII; the downstream 3790 bp of CIITA was obtained by digesting pCMV.ciita with ScaI and DraIII, and the two fragments were ligated.

pEG.ciita.N29: A pair of PCR primers was designed 25 in order to fuse the N-terminal 29% of CIITA in-frame into pEG202, following the 202nd codon of the LexA N-terminus. The sequence for the 5' back primer is AATGGATCcggttgctggctcca (upper case letters indicating the tagged sequence which includes a BamHI site for in- 30 frame cloning) and the sequence of the 3' forward primer is CCGCTCGAGcggcaccatacgtgt (the tagged sequence includes an XhoI site). These primers were used with the full length CIITA cDNA template in polymerase chain reaction (PCR) to generate a 1060 bp fragment. The PCR reaction 35 profiles were 3 cycles of 95°C for 5 minutes, 55°C for 5

2197233

- 32 -

minutes, and 72°C for 3 minutes; followed by 30 cycles of 95°C for 1 minute, 60°C for 2 minutes, and 72°C for 1 minute. The resulting DNA fragment was digested with *Bam*HI and *Xho*I, and cloned into the corresponding *Bam*HI and *Xho*I sites of the pEG202 vector. The stop codon for this fusion protein is provided by the vector sequence following the *Xho*I site of pEG202.

pcMV and pLB-1: pcMV is an EBV over-expression vector generated by partial digestion of pREP7 (Invitrogen) with *Sal*I; insertion of a *Bgl*III linker into the second *Sal*I site (nt.1091) after blunting it with Klenow; double digestion with *Hind*III and *Bgl*III; and finally ligation with the CMV promoter fragment from pCDM8 (Invitrogen), which was prepared by *Spe*I digestion of pCDM8; blunting with Klenow; *Bgl*III linker insertion; and *Hind*III and *Bgl*III digestion and gel-purification. The actual vector used to make the first ciita (lower-case letters indicate the construct was a PCR-derived product) subconstruct was pLB-1, which was derived from pcMV by inserting a ~1 kb stuffer DNA between the *Hind*III and *Not*I sites to facilitate *Hind*III/*Not*I double digestion.

pEG.CIITA.C74: pEG202 was linearized with *Bam*III, blunted with T4 polymerase and activated with *Sal*I; the insert was prepared by digesting pcMV.CIITA with *Sph*I, blunting with T4 polymerase, and activating with *Sal*I; the two fragments were then ligated.

pEG.CIITA.C50: pEG202 was linearized with *Eco*RI, blunted with T4 polymerase and activated with *Sal*I; the insert was prepared by digesting pcMV.CIITA with *Nco*I, blunting with T4 polymerase, and activating with *Sal*I; the two fragments were then ligated.

pEG.CIITA.C30: pEG202 was linearized with *Bam*HI, blunted with T4 polymerase, and activated with *Sal*I; the insert was prepared by digesting pcMV.CIITA with *Kpn*I,

- 33 -

blunting with T4 polymerase, and activating with *Sall*;
the two fragments were then ligated.

PEG.CIITA.C14: pEG.CiITA was completely cut with
*Bam*HI, diluted, and ligated. A recircularized deletion
5 construct which contains the CIITA ORF N-14% was isolated
using standard techniques.

PEG.ciita.N70: pEG202 was linearized with *Xho*I,
blunted with T4 polymerase, and activated with *Bam*HI.
The insert was prepared by digesting pET.ciITA with *Kpn*I,
10 blunting with T4 polymerase, and activating with *Bam*HI;
the two fragments were then ligated. pET.ciITA, a
construct for over-expression of CIITA, was made by
cloning the CIITA open reading frame, as in the
construction of pEG.ciITA (above), into pET28c (Novagen).

15 **PEG.ciita.N56:** pEG202 was linearized with *Xho*I,
blunted with T4 polymerase and activated with *Bam*HI; the
insert was prepared by digesting pET.ciITA with *Sfi*I,
blunting with T4 polymerase, and activating with *Bam*HI;
the two fragments were then ligated.

20 **PEG.ciita.N22:** The insert was obtained by
digesting the ciita-containing *Nhe*I/*Xho*I fragment of
pTrc5 with *Ban*I, blunting with T4 polymerase and cutting
with *Bam*HI. The vector was prepared by linearizing
pEG202 with *Xho*I, blunting with T4 polymerase and finally
25 cutting with *Bam*HI. The prepared insert and vector then
were ligated.

PEG.ciita.N17: The insert was obtained by
digesting the small *Nhe*I/*Xho*I fragment of pTrc5 with
*Eae*I, blunting with T4 polymerase and finally cutting
30 with *Bam*HI. The vector was prepared by linearizing
pEG202 with *Xho*I, blunting with T4 polymerase and finally
cutting with *Bam*HI. The prepared insert and vector then
were ligated.

PEG.ciita.N12: The insert was obtained by
35 digesting the small *Nhe*I/*Xho*I fragment of pTrc5 with

2197233

- 34 -

MspI, blunting with T4 polymerase and finally cutting with *BamHI*. The vector was prepared by linearizing pEG202 with *SallI*, blunting with T4 polymerase and finally cutting with *BamHI*. The prepared insert and vector then
5 were ligated in frame.

pEG.ciita.N7.6: The insert was obtained by digesting the small *NheI/XhoI* fragment of pTrc5 with *EcoNI*, blunting with T4 polymerase and finally cutting with *BamHI*; the vector was prepared by linearizing pEG202
10 with *XhoI*, blunting with T4 polymerase and finally cutting with *BamHI*. The prepared insert and vector then were ligated.

pEG.C- α TDF: This construct was made by inserting the C-terminal 16% of HSV1 (strain F) α -transducing
15 factor (Pellett-et al., 1985, PNAS 82:5870-5874; accession number K03350) into pEG202.

pEG.C'- α TDF: This construct was made by inserting the C-terminal 16% (except the very C-terminal 3 codons,) of HSV1 (strain F) α -transducing factor. The insert in
20 this construct was later used to construct pCMV. α TDF-CIITA.C70.

pCMV.ciita Δ HindIII: This construct contains the CIITA N-terminal 29% of the ORF, and was made by digesting pCMV.ciita with *HinddIII*, purifying the major
25 band and recircularizing.

pCMV.CIITA.C74: This construct contains the N-terminal 25 codons and about 74% of the C-terminal ORF of CIITA. It was generated by multistep subcloning. First, pKS/CIITA(+) was cut with *NcoI*, blunted with T4
30 polymerase and then cut with *XhoI* as the vector. In parallel, it was cut with *SphI*, blunted with T4 polymerase, and then cut with *XhoI* as the insert. The two fragments were ligated with T4 polymerase, and the resulting construct was termed pKS.CIITA Δ N/S. To
35 generate pCMV.CIITA.C74, pKS.CIITA Δ N/S was cut with *SpeI*

2197233

- 35 -

and *Xho*I, and the CIITA-containing fragment was then inserted into *Nhe*I/*Xho*I cut pCMV vector.

pCMV. α TDF-CIITA.C70: This was generated by multistep subcloning. First, pKS/CIITA(+) was cut with
5 *Tth*111I, blunted with T4 polymerase, and then ligated with T4 ligase. This intermediate construct was termed pKS/CIITA. Δ Tth. It was then cut with *Nco*I and *Aat*II, blunted with T4 polymerase, and ligated in-frame with a
10 very C-terminal 3 codons) of HSV1 (strain F) α -transducing factor. This second intermediate construct was termed pKS/ α TDF-CIITA. Δ Tth. The 5' α TDF-CIITA containing *Not*I fragment was then used to replace the corresponding 5' *Not*I fragment of pKS/CIITA(+). This
15 third intermediate construct was termed pKS/ α TDF-CIITAC.70. To generate pCMV. α TDF-CIITA.C70, pKS/ α TDF-CIITAC.70 was cut with *Spe*I and *Xho*I. The α TDF-CIITA containing fragment was then inserted into *Nhe*I/*Xho*I cut pCMV vector.

- 36 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Glimcher, Laurie H.
Zhou, Hong
Douhan III, John
- (ii) TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS USEFUL
FOR TREATING AUTOIMMUNE DISEASES
- (iii) NUMBER OF SEQUENCES: 1
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Fish & Richardson
(B) STREET: 225 Franklin Street
(C) CITY: Boston
(D) STATE: MA
(E) COUNTRY: USA
(F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30B
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Freeman, John W.
(B) REGISTRATION NUMBER: 29,066
(C) REFERENCE/DOCKET NUMBER: 00246/188001

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3393 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..3393
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| ATG | CGT | TGC | CTG | GCT | CCA | CGC | CCT | GCT | GGG | TCC | TAC | CTG | TCA | GAG | CCC | 48 |
| Met | Arg | Cys | Leu | Ala | Pro | Arg | Pro | Ala | Gly | Ser | Tyr | Leu | Ser | Glu | Pro | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| CAA | GGC | AGC | TCA | CAG | TGT | GCC | ACC | ATG | GAG | TTG | GGG | CCC | CTA | GAA | GGT | 96 |
| Gln | Gly | Ser | Ser | Gln | Cys | Ala | Thr | Met | Glu | Leu | Gly | Pro | Leu | Glu | Gly | |
| | | | | 20 | | | | 25 | | | | | | 30 | | |

- 37 -

GGC	TAC	CTG	GAG	CTT	CTT	AAC	AGC	GAT	GCT	GAC	CCC	CTG	TGC	CTC	TAC	144
Gly	Tyr	Leu	Glu	Leu	Leu	Asn	Ser	Asp	Ala	Asp	Pro	Leu	Cys	Leu	Tyr	
		35					40					45				
CAC	TTC	TAT	GAC	CAG	ATG	GAC	CTG	GCT	GGA	GAA	GAA	GAG	ATT	GAG	CTC	192
His	Phe	Tyr	Asp	Gln	Met	Asp	Leu	Ala	Gly	Glu	Glu	Glu	Ile	Glu	Leu	
	50					55				60						
TAC	TCA	GAA	CCC	GAC	ACA	GAC	ACC	ATC	AAC	TGC	GAC	CAG	TTC	AGC	AGG	240
Tyr	Ser	Glu	Pro	Asp	Thr	Asp	Thr	Ile	Asn	Cys	Asp	Gln	Phe	Ser	Arg	
	65				70					75					80	
CTG	TTG	TGT	GAC	ATG	GAA	GGT	GAT	GAA	GAG	ACC	AGG	GAG	GCT	TAT	GCC	288
Leu	Leu	Cys	Asp	Met	Glu	Gly	Asp	Glu	Glu	Thr	Arg	Glu	Ala	Tyr	Ala	
				85					90					95		
AAT	ATC	GCG	GAA	CTG	GAC	CAG	TAT	GTC	TTC	CAG	GAC	TCC	CAG	CTG	GAG	336
Asn	Ile	Ala	Glu	Leu	Asp	Gln	Tyr	Val	Phe	Gln	Asp	Ser	Gln	Leu	Glu	
		100						105					110			
GGC	CTG	AGC	AAG	GAC	ATT	TTC	AAG	CAC	ATA	GGA	CCA	GAT	GAA	GTG	ATC	384
Gly	Leu	Ser	Lys	Asp	Ile	Phe	Lys	His	Ile	Gly	Pro	Asp	Glu	Val	Ile	
		115					120					125				
GGT	GAG	AGT	ATG	GAG	ATG	CCA	GCA	GAA	GTT	GGG	CAG	AAA	AGT	CAG	AAA	432
Gly	Glu	Ser	Met	Glu	Met	Pro	Ala	Glu	Val	Gly	Gln	Lys	Ser	Gln	Lys	
	130					135					140					
AGA	CCC	TTC	CCA	GAG	GAG	CTT	CCG	GCA	GAC	CTG	AAG	CAC	TGG	AAG	CCA	480
Arg	Pro	Phe	Pro	Glu	Glu	Leu	Pro	Ala	Asp	Leu	Lys	His	Trp	Lys	Pro	
	145				150					155					160	
GCT	GAG	CCC	CCC	ACT	GTG	GTG	ACT	GGC	AGT	CTC	CTA	GTG	GGA	CCA	GTG	528
Ala	Glu	Pro	Pro	Thr	Val	Val	Thr	Gly	Ser	Leu	Leu	Val	Gly	Pro	Val	
				165				170					175			
AGC	GAC	TGC	TCC	ACC	CTG	CCC	TGC	CTG	CCA	CTG	CCT	GCG	CTG	TTC	AAC	576
Ser	Asp	Cys	Ser	Thr	Leu	Pro	Cys	Leu	Pro	Leu	Pro	Ala	Leu	Phe	Asn	
		180					185						190			
CAG	GAG	CCA	GCC	TCC	GGC	CAG	ATG	CGC	CTG	GAG	AAA	ACC	GAC	CAG	ATT	624
Gln	Glu	Pro	Ala	Ser	Gly	Gln	Met	Arg	Leu	Glu	Lys	Thr	Asp	Gln	Ile	
		195					200					205				
CCC	ATG	CCT	TTC	TCC	AGT	TCC	TCG	TTG	AGC	TGC	CTG	AAT	CTC	CCT	GAG	672
Pro	Met	Pro	Phe	Ser	Ser	Ser	Ser	Leu	Ser	Cys	Leu	Asn	Leu	Pro	Glu	
	210					215					220					
GGA	CCC	ATC	CAG	TTT	GTC	CCC	ACC	ATC	TCC	ACT	CTG	CCC	CAT	GGG	CTC	720
Gly	Pro	Ile	Gln	Phe	Val	Pro	Thr	Ile	Ser	Thr	Leu	Pro	His	Gly	Leu	
	225				230				235						240	
TGG	CAA	ATC	TCT	GAG	GCT	GGA	ACA	GGG	GTC	TCC	AGT	ATA	TTC	ATC	TAC	768
Trp	Gln	Ile	Ser	Glu	Ala	Gly	Thr	Gly	Val	Ser	Ser	Ile	Phe	Ile	Tyr	
				245				250						255		
CAT	GGT	GAG	GTG	CCC	CAG	GCC	AGC	CAA	GTA	CCC	CCT	CCC	AGT	GGA	TTC	816
His	Gly	Glu	Val	Pro	Gln	Ala	Ser	Gln	Val	Pro	Pro	Pro	Ser	Gly	Phe	
			260					265					270			
ACT	GTC	CAC	GGC	CTC	CCA	ACA	TCT	CCA	GAC	CGG	CCA	GGC	TCC	ACC	AGC	864
Thr	Val	His	Gly	Leu	Pro	Thr	Ser	Pro	Asp	Arg	Pro	Gly	Ser	Thr	Ser	
		275					280					285				

- 38 -

CCC	TTC	GCT	CCA	TCA	GCC	ACT	GAC	CTG	CCC	AGC	ATG	CCT	GAA	CCT	GCC	912
Pro	Phe	Ala	Pro	Ser	Ala	Thr	Asp	Leu	Pro	Ser	Met	Pro	Glu	Pro	Ala	
290						295					300					
CTG	ACC	TCC	CGA	GCA	AAC	ATG	ACA	GAG	CAC	AAG	ACG	TCC	CCC	ACC	CAA	960
Leu	Thr	Ser	Arg	Ala	Asn	Met	Thr	Glu	His	Lys	Thr	Ser	Pro	Thr	Gln	
305					310					315					320	
TGC	CCG	GCA	GCT	GGA	GAG	GTC	TCC	AAC	AAG	CTT	CCA	AAA	TGG	CCT	GAG	1008
Cys	Pro	Ala	Ala	Gly	Glu	Val	Ser	Asn	Lys	Leu	Pro	Lys	Trp	Pro	Glu	
				325					330					335		
CCG	GTG	GAG	CAG	TTC	TAC	CGC	TCA	CTG	CAG	GAC	ACG	TAT	GGT	GCC	GAG	1056
Pro	Val	Glu	Gln	Phe	Tyr	Arg	Ser	Leu	Gln	Asp	Thr	Tyr	Gly	Ala	Glu	
			340					345					350			
CCC	GCA	GGC	CCG	GAT	GGC	ATC	CTA	GTG	GAG	GTG	GAT	CTG	GTG	CAG	GCC	1104
Pro	Ala	Gly	Pro	Asp	Gly	Ile	Leu	Val	Glu	Val	Asp	Leu	Val	Gln	Ala	
		355					360					365				
AGG	CTG	GAG	AGG	AGC	AGC	AGC	AAG	AGC	CTG	GAG	CGG	GAA	CTG	GCC	ACC	1152
Arg	Leu	Glu	Arg	Ser	Ser	Ser	Lys	Ser	Leu	Glu	Arg	Glu	Leu	Ala	Thr	
	370					375					380					
CCG	GAC	TGG	GCA	GAA	CGG	CAG	CTG	GCC	CAA	GGA	GGC	CTG	GCT	GAG	GTG	1200
Pro	Asp	Trp	Ala	Glu	Arg	Gln	Leu	Ala	Gln	Gly	Gly	Leu	Ala	Glu	Val	
385					390					395					400	
CTG	TTG	GCT	GCC	AAG	GAG	CAC	CGG	CGG	CCG	CGT	GAG	ACA	CGA	GTG	ATT	1248
Leu	Leu	Ala	Ala	Lys	Glu	His	Arg	Arg	Pro	Arg	Glu	Thr	Arg	Val	Ile	
				405					410					415		
GCT	GTG	CTG	GGC	AAA	GCT	GGT	CAG	GGC	AAG	AGC	TAT	TGG	GCT	GGG	GCA	1296
Ala	Val	Leu	Gly	Lys	Ala	Gly	Gln	Gly	Lys	Ser	Tyr	Trp	Ala	Gly	Ala	
			420					425					430			
GTG	AGC	CGG	GCC	TGG	GCT	TGT	GGC	CGG	CTT	CCC	CAG	TAC	GAC	TTT	GTC	1344
Val	Ser	Arg	Ala	Trp	Ala	Cys	Gly	Arg	Leu	Pro	Gln	Tyr	Asp	Phe	Val	
		435					440					445				
TTC	TCT	GTC	CCC	TGC	CAT	TGC	TTG	AAC	CGT	CCG	GGG	GAT	GCC	TAT	GGC	1392
Phe	Ser	Val	Pro	Cys	His	Cys	Leu	Asn	Arg	Pro	Gly	Asp	Ala	Tyr	Gly	
	450					455					460					
CTG	CAG	GAT	CTG	CTC	TTC	TCC	CTG	GGC	CCA	CAG	CCA	CTC	GTG	GCG	GCC	1440
Leu	Gln	Asp	Leu	Leu	Phe	Ser	Leu	Gly	Pro	Gln	Pro	Leu	Val	Ala	Ala	
465					470					475					480	
GAT	GAG	GTT	TTC	AGC	CAC	ATC	TTG	AAG	AGA	CCT	GAC	CGC	GTT	CTG	CTC	1488
Asp	Glu	Val	Phe	Ser	His	Ile	Leu	Lys	Arg	Pro	Asp	Arg	Val	Leu	Leu	
				485					490					495		
ATC	CTA	GAC	GCC	TTC	GAG	GAG	CTG	GAA	GCG	CAA	GAT	GGC	TTC	CTG	CAC	1536
Ile	Leu	Asp	Ala	Phe	Glu	Glu	Leu	Glu	Ala	Gln	Asp	Gly	Phe	Leu	His	
			500					505				510				
AGC	ACG	TGC	GGA	CCG	GCA	CCG	GCG	GAG	CCC	TGC	TCC	CTC	CGG	GGG	CTG	1584
Ser	Thr	Cys	Gly	Pro	Ala	Pro	Ala	Glu	Pro	Cys	Ser	Leu	Arg	Gly	Leu	
		515					520					525				
CTG	GCC	GGC	CTT	TTC	CAG	AAG	AAG	CTG	CTC	CGA	GGT	TGC	ACC	CTC	CTC	1632
Leu	Ala	Gly	Leu	Phe	Gln	Lys	Lys	Leu	Leu	Arg	Gly	Cys	Thr	Leu	Leu	
	530					535					540					

- 39 -

CTC Leu 545	ACA Thr	GCC Ala	CGG Arg	CCC Pro	CGG Arg 550	GGC Gly	CGC Arg	CTG Leu	GTC Val	CAG Gln 555	AGC Ser	CTG Leu	AGC Ser	AAG Lys	GCC Ala 560	1680
GAC Asp	GCC Ala	CTA Leu	TTT Phe 565	GAG Glu	CTG Leu	TCC Ser	GGC Gly	TTC Phe	TCC Ser 570	ATG Met	GAG Glu	CAG Gln	GCC Ala	CAG Gln 575	GCA Ala	1728
TAC Tyr	GTG Val	ATG Met	CGC Arg 580	TAC Tyr	TTT Phe	GAG Glu	AGC Ser	TCA Ser 585	GGG Gly	ATG Met	ACA Thr	GAG Glu	CAC His 590	CAA Gln	GAC Asp	1776
AGA Arg	GCC Ala	CTG Leu 595	ACG Thr	CTC Leu	CTC Leu	CGG Arg	GAC Asp 600	CGG Arg	CCA Pro	CTT Leu	CTT Leu	CTC Leu 605	AGT Ser	CAC His	AGC Ser	1824
CAC His 610	AGC Ser	CCT Pro	ACT Thr	TTG Leu	TGC Cys	CGG Arg 615	GCA Ala	GTG Val	TGC Cys	CAG Gln 620	CTC Leu	TCA Ser	GAG Glu	GCC Ala	CTG Leu	1872
CTG Leu 625	GAG Glu	CTT Leu	GGG Gly	GAG Glu	GAC Asp 630	GCC Ala	AAG Lys	CTG Leu	CCC Pro	TCC Ser 635	ACG Thr	CTC Leu	ACG Thr	GGA Gly	CTC Leu 640	1920
TAT Tyr	GTC Val	GGC Gly	CTG Leu 645	CTG Leu	GGC Gly	CGT Arg	GCA Ala	GCC Ala	CTC Leu 650	GAC Asp	AGC Ser	CCC Pro	CCC Pro	GGG Gly 655	GCC Ala	1968
CTG Leu	GCA Ala	GAG Glu	CTG Leu 660	GCC Ala	AAG Lys	CTG Leu	GCC Ala	TGG Trp 665	GAG Glu	CTG Leu	GGC Gly	CGC Arg	AGA Arg 670	CAT His	CAA Gln	2016
AGT Ser	ACC Thr	CTA Leu 675	CAG Gln	GAG Glu	GAC Asp	CAG Gln	TTC Phe 680	CCA Pro	TCC Ser	GCA Ala	GAC Asp	GTG Val 685	AGG Arg	ACC Thr	TGG Trp	2064
GCG Ala 690	ATG Met	GCC Ala	AAA Lys	GGC Gly	TTA Leu	GTC Val 695	CAA Gln	CAC His	CCA Pro	CCG Pro	CGG Arg 700	GCC Ala	GCA Ala	GAG Glu	TCC Ser	2112
GAG Glu 705	CTG Leu	GCC Ala	TTC Phe	CCC Pro	AGC Ser 710	TTC Phe	CTC Leu	CTG Leu	CAA Gln	TGC Cys 715	TTC Phe	CTG Leu	GGG Gly	GCC Ala	CTG Leu 720	2160
TGG Trp	CTG Leu	GCT Ala	CTG Leu 725	AGT Ser	GGC Gly	GAA Glu	ATC Ile	AAG Lys	GAC Asp 730	AAG Lys	GAG Glu	CTC Leu	CCG Pro	CAG Gln 735	TAC Tyr	2208
CTA Leu	GCA Ala	TTG Leu	ACC Thr 740	CCA Pro	AGG Arg	AAG Lys	AAG Lys	AGG Arg 745	CCC Pro	TAT Tyr	GAC Asp	AAC Asn	TGG Trp 750	CTG Leu	GAG Glu	2256
GGC Gly 755	GTG Val	CCA Pro	CGC Arg	TTT Phe	CTG Leu	GCT Ala 760	GGG Gly	CTG Leu	ATC Ile	TTC Phe	CAG Gln	CCT Pro 765	CCC Pro	GCC Ala	CGC Arg	2304
TGC Cys 770	CTG Leu	GGA Gly	GCC Ala	CTA Leu	CTC Leu	GGG Gly 775	CCA Pro	TCG Ser	GCG Ala	GCT Ala	GCC Ala 780	TCG Ser	GTG Val	GAC Asp	AGG Arg	2352
AAG Lys 785	CAG Gln	AAG Lys	GTG Val	CTT Leu	GCG Ala 790	AGG Arg	TAC Tyr	CTG Leu	AAG Lys	CGG Arg 795	CTG Leu	CAG Gln	CCG Pro	GGG Gly	ACA Thr 800	2400

- 40 -

CTG	CGG	GCG	CGG	CAG	CTG	CTT	GAG	CTG	CTG	CAC	TGC	GCC	CAC	GAG	GCC	2448
Leu	Arg	Ala	Arg	Gln	Leu	Leu	Glu	Leu	Leu	His	Cys	Ala	His	Glu	Ala	
				805					810					815		
GAG	GAG	GCT	GGA	ATT	TGG	CAG	CAC	GTG	GTA	CAG	GAG	CTC	CCC	GGC	CGC	2496
Glu	Glu	Ala	Gly	Ile	Trp	Gln	His	Val	Val	Gln	Glu	Leu	Pro	Gly	Arg	
			820					825					830			
CTC	TCT	TTT	CTG	GGC	ACC	CGC	CTC	ACG	CCT	CCT	GAT	GCA	CAT	GTA	CTG	2544
Leu	Ser	Phe	Leu	Gly	Thr	Arg	Leu	Thr	Pro	Pro	Asp	Ala	His	Val	Leu	
		835					840					845				
GGC	AAG	GCC	TTG	GAG	GCG	GCG	GGC	CAA	GAC	TTC	TCC	CTG	GAC	CTC	CGC	2592
Gly	Lys	Ala	Leu	Glu	Ala	Ala	Gly	Gln	Asp	Phe	Ser	Leu	Asp	Leu	Arg	
	850					855					860					
AGC	ACT	GGC	ATT	TGC	CCC	TCT	GGA	TTG	GGG	AGC	CTC	GTG	GGA	CTC	AGC	2640
Ser	Thr	Gly	Ile	Cys	Pro	Ser	Gly	Leu	Gly	Ser	Leu	Val	Gly	Leu	Ser	
865					870					875					880	
TGT	GTC	ACC	CGT	TTC	AGG	GCT	GCC	TTG	AGC	GAC	ACG	GTG	GCG	CTG	TGG	2688
Cys	Val	Thr	Arg	Phe	Arg	Ala	Ala	Leu	Ser	Asp	Thr	Val	Ala	Leu	Trp	
				885					890					895		
GAG	TCC	CTG	CGG	CAG	CAT	GGG	GAG	ACC	AAG	CTA	CTT	CAG	GCA	GCA	GAG	2736
Glu	Ser	Leu	Arg	Gln	His	Gly	Glu	Thr	Lys	Leu	Leu	Gln	Ala	Ala	Glu	
			900					905					910			
GAG	AAG	TTC	ACC	ATC	GAG	CCT	TTC	AAA	GCC	AAG	TCC	CTG	AAG	GAT	GTG	2784
Glu	Lys	Phe	Thr	Ile	Glu	Pro	Phe	Lys	Ala	Lys	Ser	Leu	Lys	Asp	Val	
		915					920					925				
GAA	GAC	CTG	GGA	AAG	CTT	GTG	CAG	ACT	CAG	AGG	ACG	AGA	AGT	TCC	TCG	2832
Glu	Asp	Leu	Gly	Lys	Leu	Val	Gln	Thr	Gln	Arg	Thr	Arg	Ser	Ser	Ser	
	930					935					940					
GAA	GAC	ACA	GCT	GGG	GAG	CTC	CCT	GCT	GTT	CGG	GAC	CTA	AAG	AAA	CTG	2880
Glu	Asp	Thr	Ala	Gly	Glu	Leu	Pro	Ala	Val	Arg	Asp	Leu	Lys	Lys	Leu	
945				950						955					960	
GAG	TTT	GCG	CTG	GGC	CCT	GTC	TCA	GGC	CCC	CAG	GCT	TTC	CCC	AAA	CTG	2928
Glu	Phe	Ala	Leu	Gly	Pro	Val	Ser	Gly	Pro	Gln	Ala	Phe	Pro	Lys	Leu	
				965					970					975		
GTG	CGG	ATC	CTC	ACG	GCC	TTT	TCC	TCC	CTG	CAG	CAT	CTG	GAC	CTG	GAT	2976
Val	Arg	Ile	Leu	Thr	Ala	Phe	Ser	Ser	Leu	Gln	His	Leu	Asp	Leu	Asp	
			980					985					990			
GCG	CTG	AGT	GAG	AAC	AAG	ATC	GGG	GAC	GAG	GGT	GTC	TCG	CAG	CTC	TCA	3024
Ala	Leu	Ser	Glu	Asn	Lys	Ile	Gly	Asp	Glu	Gly	Val	Ser	Gln	Leu	Ser	
		995					1000					1005				
GCC	ACC	TTC	CCC	CAG	CTG	AAG	TCC	TTG	GAA	ACC	CTC	AAT	CTG	TCC	CAG	3072
Ala	Thr	Phe	Pro	Gln	Leu	Lys	Ser	Leu	Glu	Thr	Leu	Asn	Leu	Ser	Gln	
	1010					1015					1020					
AAC	AAC	ATC	ACT	GAC	CTG	GGT	GCC	TAC	AAA	CTC	GCC	GAG	GCC	CTG	CCT	3120
Asn	Asn	Ile	Thr	Asp	Leu	Gly	Ala	Tyr	Lys	Leu	Ala	Glu	Ala	Leu	Pro	
1025					1030					1035					1040	
TCG	CTC	GCT	GCA	TCC	CTG	CTC	AGG	CTA	AGC	TTG	TAC	AAT	AAC	TGC	ATC	3168
Ser	Leu	Ala	Ala	Ser	Leu	Leu	Arg	Leu	Ser	Leu	Tyr	Asn	Asn	Cys	Ile	
				1045					1050					1055		

- 41 -

TGC GAC GTG GGA GCC GAG AGC TTG GCT CGT GTG CTT CCG GAC ATG GTG Cys Asp Val Gly Ala Glu Ser Leu Ala Arg Val Leu Pro Asp Met Val 1060 1065 1070	3216
TCC CTC CGG GTG ATG GAC GTC CAG TAC AAC AAG TTC ACG GCT GCC GGG Ser Leu Arg Val Met Asp Val Gln Tyr Asn Lys Phe Thr Ala Ala Gly 1075 1080 1085	3264
GCC CAG CAG CTC GCT GCC AGC CTT CGG AGG TGT CCT CAT GTG GAG ACG Ala Gln Gln Leu Ala Ala Ser Leu Arg Arg Cys Pro His Val Glu Thr 1090 1095 1100	3312
CTG GCG ATG TGG ACG CCC ACC ATC CCA TTC AGT GTC CAG GAA CAC CTG Leu Ala Met Trp Thr Pro Thr Ile Pro Phe Ser Val Gln Glu His Leu 1105 1110 1115 1120	3360
CAA CAA CAG GAT TCA CGG ATC AGC CTG AGA TGA Gln Gln Gln Asp Ser Arg Ile Ser Leu Arg * 1125 1130	3393

-42-

CLAIMS:

1. A method of determining whether a compound inhibits the ability of a polypeptide to activate transcription, the polypeptide being characterized in that it comprises a CIITA transcription activation domain and lacks a functional CIITA interaction domain, wherein inhibition of transcription indicates that said compound is a potential autoimmune disease therapeutic.

2. The method of claim 1, wherein inhibition of transcription activation is measured by

a) providing a fusion protein comprising said polypeptide fused to a DNA-binding protein;

b) providing a transcription regulatory DNA sequence, operably linked to a reporter gene in a system suitable for transcribing said reporter gene when said fusion protein is bound to said regulatory DNA sequence;

c) providing said fusion protein and said compound in said system; and

d) measuring the ability of said compound to inhibit transcription of said reporter gene.

3. The method of claim 1, further comprising measuring the ability of said compound to inhibit the ability of a second polypeptide to activate transcription, the second polypeptide being characterized in that it comprises an isotype-specific CIITA transcription activation domain and lacks a functional CIITA interaction domain, wherein said method identifies isotype-specific compounds.

4. A substantially pure DNA encoding a CIITA isotype-specific transcription activating polypeptide including amino acids 26-352 of the amino acid sequence in Fig. 1, that functions as an activation domain of CIITA but not as an interaction domain of CIITA.

5. The DNA of claim 4, wherein said DNA has the sequence

-43-

of nucleotides 76-1056 of Fig. 1, or encodes a polypeptide that functions as an activation and not as an interaction domain of CIITA but differs from amino acids 26-352 of Fig. 1 by one or more conservative amino acid substitutions.

6. The DNA of claim 4, wherein said DNA has the sequence of nucleotides 76-1056 of Fig. 1, or encodes the same amino acid sequence as nucleotides 76-1056 of Fig. 1.

7. A substantially pure DNA encoding a CIITA transcription activating polypeptide including amino acids 26-352 of Fig. 1, said polypeptide functioning as an activation domain but not as an interaction domain of CIITA.

8. A substantially pure polypeptide comprising a CIITA transcription activation domain and lacking a functional CIITA interaction domain.

9. The polypeptide of claim 8 comprising an amino acid sequence substantially identical to amino acids 26-352 the amino acid sequence of Fig. 1 that functions as an activation domain, but not as an interaction domain of CIITA.

10. The polypeptide of claim 8 wherein said CIITA is isotype-specific.

11. The polypeptide of claim 8, wherein said polypeptide has the sequence of amino acids 26-352 of SEQ ID NO:1, or a polypeptide that functions as an activation and not as an interaction domain of CIITA but differs from amino acids 26-352 of SEQ ID NO:1 by one or more conservative amino acid substitutions.

12. A method of determining whether a compound inhibits the ability of a polypeptide to bind its target protein, said polypeptide being characterized in that it comprises a CIITA interaction domain and lacks a functional

-44-

CIITA activation domain, wherein inhibition of binding indicates that said compound is a potential autoimmune disease therapeutic.

13. The method of claim 12, said method comprising determining whether said compound inhibits the ability of said polypeptide to mediate transcription, inhibition of transcription indicating that said compound is a potential autoimmune disease therapeutic.

14. The method of claim 13, wherein said inhibition is measured by

a) providing a first fusion protein comprising said polypeptide fused to a DNA binding protein;

b) providing a reporter construct comprising DNA regulatory sequence for said DNA binding protein, operably linked to a reporter gene in a system suitable for transcribing said reporter gene;

c) providing a second fusion protein, said second fusion protein being characterized in that it comprises a transcription activation domain fused to the target protein of a CIITA interaction domain;

d) providing said first and second fusion proteins, said reporter construct and said compound in a transcription system; and

e) measuring the ability of said compound to inhibit transcription of said reporter gene.

15. The method of claim 12, further comprising measuring the ability of said compound to inhibit the ability of a second polypeptide to bind its target protein, said second polypeptide being characterized in that it comprises an isotype-specific CIITA interaction domain and lacks a functional CIITA transcription activation domain, wherein said method identifies isotype-specific compounds.

16. A substantially pure DNA encoding a CIITA polypeptide

-45-

including amino acids 301-1130 of Fig. 1, or a variant thereof that functions as an interaction domain of CIITA, but not as an activation domain of CIITA.

17. The DNA of claim 16, wherein said DNA has the sequence of nucleotides 903-3390 of Fig. 1, or encodes a polypeptide that functions as an interaction and not as an activation domain of CIITA but differs from amino acids 301-1130 of Fig. 1 by one or more conservative amino acid-substitutions.

18. The DNA of claim 16, wherein said DNA encodes a polypeptide comprising amino acids 301-1130 of Fig. 1.

19. The DNA of claim 16, wherein said CIITA is isotype-specific.

20. A substantially pure polypeptide comprising a CIITA interaction domain and lacking a functional CIITA transcription activation domain.

21. The polypeptide of claim 20, wherein said polypeptide has the sequence of amino acids 301-1130 of Fig. 1 or a polypeptide that functions as an interaction and not as an activation domain of CIITA but differs from amino acids 301-1130 of Fig. 1 by one or more conservative amino acid substitutions.

22. The polypeptide of claim 20, including amino acids 301-1130 of Fig. 1 that functions as an interaction domain, but not as an activation domain of CIITA.

23. The polypeptide of claim 21, wherein said CIITA is isotype-specific.

24. A method of determining whether a compound inhibits the ability of a polypeptide to mediate transcription, said polypeptide being characterized in that it comprises a CIITA

-46-

interaction domain fused to a transcription activation domain and lacks a functional CIITA transcription activation domain, wherein inhibition of transcription indicates that said compound is a potential autoimmune disease therapeutic.

25. The method of claim 24, further comprising providing said polypeptide in a B lymphocyte and assaying for expression of the MHC class II genes.

26. The method of claim 25, wherein said cell is a human B cell selected from the group consisting of clone 13 cells and RM3 cells.

2197233

IPEA/US 25 MAR 1996

1 / 18

ATG	CGT	TGC	CTG	GCT	CCA	CGC	CCT	GCT	GGG	TCC	TAC	CTG	TCA	GAG	CCC	48
Met	Arg	Cys	Leu	Ala	Pro	Arg	Pro	Ala	Gly	Ser	Tyr	Leu	Ser	Glu	Pro	
1				5					10					15		
CAA	GGC	AGC	TCA	CAG	TGT	GCC	ACC	ATG	GAG	TTG	GGG	CCC	CTA	GAA	GGT	96
Gln	Gly	Ser	Ser	Gln	Cys	Ala	Thr	Met	Glu	Leu	Gly	Pro	Leu	Glu	Gly	
			20					25					30			
GGC	TAC	CTG	GAG	CTT	CTT	AAC	AGC	GAT	GCT	GAC	CCC	CTG	TGC	CTC	TAC	144
Gly	Tyr	Leu	Glu	Leu	Leu	Asn	Ser	Asp	Ala	Asp	Pro	Leu	Cys	Leu	Tyr	
		35					40					45				
CAC	TTC	TAT	GAC	CAG	ATG	GAC	CTG	GCT	GGA	GAA	GAA	GAG	ATT	GAG	CTC	192
His	Phe	Tyr	Asp	Gln	Met	Asp	Leu	Ala	Gly	Glu	Glu	Glu	Ile	Glu	Leu	
	50					55						60				
TAC	TCA	GAA	CCC	GAC	ACA	GAC	ACC	ATC	AAC	TGC	GAC	CAG	TTC	AGC	AGG	240
Tyr	Ser	Glu	Pro	Asp	Thr	Asp	Thr	Ile	Asn	Cys	Asp	Gln	Phe	Ser	Arg	
65					70					75					80	
CTG	TTG	TGT	GAC	ATG	GAA	GGT	GAT	GAA	GAG	ACC	AGG	GAG	GCT	TAT	GCC	288
Leu	Leu	Cys	Asp	Met	Glu	Gly	Asp	Glu	Glu	Thr	Arg	Glu	Ala	Tyr	Ala	
				85					90					95		
AAT	ATC	GCG	GAA	CTG	GAC	CAG	TAT	GTC	TTC	CAG	GAC	TCC	CAG	CTG	GAG	336
Asn	Ile	Ala	Glu	Leu	Asp	Gln	Tyr	Val	Phe	Gln	Asp	Ser	Gln	Leu	Glu	
		100						105					110			
GGC	CTG	AGC	AAG	GAC	ATT	TTC	AAG	CAC	ATA	GGA	CCA	GAT	GAA	GTG	ATC	384
Gly	Leu	Ser	Lys	Asp	Ile	Phe	Lys	His	Ile	Gly	Pro	Asp	Glu	Val	Ile	
		115					120					125				
GGT	GAG	AGT	ATG	GAG	ATG	CCA	GCA	GAA	GTT	GGG	CAG	AAA	AGT	CAG	AAA	432
Gly	Glu	Ser	Met	Glu	Met	Pro	Ala	Glu	Val	Gly	Gln	Lys	Ser	Gln	Lys	
	130					135					140					
AGA	CCC	TTC	CCA	GAG	GAG	CTT	CCG	GCA	GAC	CTG	AAG	CAC	TGG	AAG	CCA	480
Arg	Pro	Phe	Pro	Glu	Glu	Leu	Pro	Ala	Asp	Leu	Lys	His	Trp	Lys	Pro	
145					150					155					160	
GCT	GAG	CCC	CCC	ACT	GTG	GTG	ACT	GGC	AGT	CTC	CTA	GTG	GGA	CCA	GTG	528
Ala	Glu	Pro	Pro	Thr	Val	Val	Thr	Gly	Ser	Leu	Leu	Val	Gly	Pro	Val	
				165					170					175		
AGC	GAC	TGC	TCC	ACC	CTG	CCC	TGC	CTG	CCA	CTG	CCT	GCG	CTG	TTC	AAC	576
Ser	Asp	Cys	Ser	Thr	Leu	Pro	Cys	Leu	Pro	Leu	Pro	Ala	Leu	Phe	Asn	
			180					185					190			
CAG	GAG	CCA	GCC	TCC	GGC	CAG	ATG	CGC	CTG	GAG	AAA	ACC	GAC	CAG	ATT	624
Gln	Glu	Pro	Ala	Ser	Gly	Gln	Met	Arg	Leu	Glu	Lys	Thr	Asp	Gln	Ile	
		195					200					205				
CCC	ATG	CCT	TTC	TCC	AGT	TCC	TCG	TTG	AGC	TGC	CTG	AAT	CTC	CCT	GAG	672
Pro	Met	Pro	Phe	Ser	Ser	Ser	Ser	Leu	Ser	Cys	Leu	Asn	Leu	Pro	Glu	
	210					215					220					
GGA	CCC	ATC	CAG	TTT	GTC	CCC	ACC	ATC	TCC	ACT	CTG	CCC	CAT	GGG	CTC	720
Gly	Pro	Ile	Gln	Phe	Val	Pro	Thr	Ile	Ser	Thr	Leu	Pro	His	Gly	Leu	
225					230					235					240	
TGG	CAA	ATC	TCT	GAG	GCT	GGA	ACA	GGG	GTC	TCC	AGT	ATA	TTC	ATC	TAC	768
Trp	Gln	Ile	Ser	Glu	Ala	Gly	Thr	Gly	Val	Ser	Ser	Ile	Phe	Ile	Tyr	
				245					250					255		
CAT	GGT	GAG	GTG	CCC	CAG	GCC	AGC	CAA	GTA	CCC	CCT	CCC	AGT	GGA	TTC	816
His	Gly	Glu	Val	Pro	Gln	Ala	Ser	Gln	Val	Pro	Pro	Pro	Ser	Gly	Phe	
			260					265					270			

FIG. 1A

AMENDED SHEET

2197233

PCT/US9 5 / 10 6 9 1
IPEA/US 25 MAR 1996

2 / 18

ACT	GTC	CAC	GGC	CTC	CCA	ACA	TCT	CCA	GAC	CGG	CCA	GGC	TCC	ACC	AGC	864
Thr	Val	His	Gly	Leu	Pro	Thr	Ser	Pro	Asp	Arg	Pro	Gly	Ser	Thr	Ser	
		275					280					285				
CCC	TTC	GCT	CCA	TCA	GCC	ACT	GAC	CTG	CCC	AGC	ATG	CCT	GAA	CCT	GCC	912
Pro	Phe	Ala	Pro	Ser	Ala	Thr	Asp	Leu	Pro	Ser	Met	Pro	Glu	Pro	Ala	
	290					295					300					
CTG	ACC	TCC	CGA	GCA	AAC	ATG	ACA	GAG	CAC	AAG	ACG	TCC	CCC	ACC	CAA	960
Leu	Thr	Ser	Arg	Ala	Asn	Met	Thr	Glu	His	Lys	Thr	Ser	Pro	Thr	Gln	
305					310					315					320	
TGC	CCG	GCA	GCT	GGA	GAG	GTC	TCC	AAC	AAG	CTT	CCA	AAA	TGG	CCT	GAG	1008
Cys	Pro	Ala	Ala	Gly	Glu	Val	Ser	Asn	Lys	Leu	Pro	Lys	Trp	Pro	Glu	
				325					330					335		
CCG	GTG	GAG	CAG	TTC	TAC	CGC	TCA	CTG	CAG	GAC	ACG	TAT	GGT	GCC	GAG	1056
Pro	Val	Glu	Gln	Phe	Tyr	Arg	Ser	Leu	Gln	Asp	Thr	Tyr	Gly	Ala	Glu	
			340					345					350			
CCC	GCA	GGC	CCG	GAT	GGC	ATC	CTA	GTG	GAG	GTG	GAT	CTG	GTG	CAG	GCC	1104
Pro	Ala	Gly	Pro	Asp	Gly	Ile	Leu	Val	Glu	Val	Asp	Leu	Val	Gln	Ala	
		355					360					365				
AGG	CTG	GAG	AGG	AGC	AGC	AGC	AAG	AGC	CTG	GAG	CGG	GAA	CTG	GCC	ACC	1152
Arg	Leu	Glu	Arg	Ser	Ser	Ser	Lys	Ser	Leu	Glu	Arg	Glu	Leu	Ala	Thr	
	370					375					380					
CCG	GAC	TGG	GCA	GAA	CGG	CAG	CTG	GCC	CAA	GGA	GGC	CTG	GCT	GAG	GTG	1200
Pro	Asp	Trp	Ala	Glu	Arg	Gln	Leu	Ala	Gln	Gly	Gly	Leu	Ala	Glu	Val	
385					390					395					400	
CTG	TTG	GCT	GCC	AAG	GAG	CAC	CGG	CGG	CCG	CGT	GAG	ACA	CGA	GTG	ATT	1248
Leu	Leu	Ala	Ala	Lys	Glu	His	Arg	Arg	Pro	Arg	Glu	Thr	Arg	Val	Ile	
				405					410					415		
GCT	GTG	CTG	GGC	AAA	GCT	GGT	CAG	GGC	AAG	AGC	TAT	TGG	GCT	GGG	GCA	1296
Ala	Val	Leu	Gly	Lys	Ala	Gly	Gln	Gly	Lys	Ser	Tyr	Trp	Ala	Gly	Ala	
			420					425					430			
GTG	AGC	CGG	GCC	TGG	GCT	TGT	GGC	CGG	CTT	CCC	CAG	TAC	GAC	TTT	GTC	1344
Val	Ser	Arg	Ala	Trp	Ala	Cys	Gly	Arg	Leu	Pro	Gln	Tyr	Asp	Phe	Val	
		435					440					445				
TTC	TCT	GTC	CCC	TGC	CAT	TGC	TTG	AAC	CGT	CCG	GGG	GAT	GCC	TAT	GGC	1392
Phe	Ser	Val	Pro	Cys	His	Cys	Leu	Asn	Arg	Pro	Gly	Asp	Ala	Tyr	Gly	
	450					455					460					
CTG	CAG	GAT	CTG	CTC	TTC	TCC	CTG	GGC	CCA	CAG	CCA	CTC	GTG	GCG	GCC	1440
Leu	Gln	Asp	Leu	Leu	Phe	Ser	Leu	Gly	Pro	Gln	Pro	Leu	Val	Ala	Ala	
465					470					475					480	
GAT	GAG	GTT	TTC	AGC	CAC	ATC	TTG	AAG	AGA	CCT	GAC	CGC	GTT	CTG	CTC	1488
Asp	Glu	Val	Phe	Ser	His	Ile	Leu	Lys	Arg	Pro	Asp	Arg	Val	Leu	Leu	
				485					490					495		
ATC	CTA	GAC	GCC	TTC	GAG	GAG	CTG	GAA	GCG	CAA	GAT	GGC	TTC	CTG	CAC	1536
Ile	Leu	Asp	Ala	Phe	Glu	Glu	Leu	Glu	Ala	Gln	Asp	Gly	Phe	Leu	His	
			500					505					510			
AGC	ACG	TGC	GGA	CCG	GCA	CCG	GCG	GAG	CCC	TGC	TCC	CTC	CGG	GGG	CTG	1584
Ser	Thr	Cys	Gly	Pro	Ala	Pro	Ala	Glu	Pro	Cys	Ser	Leu	Arg	Gly	Leu	
		515					520					525				

FIG. 1B

AMENDED SHEET

2197233

IPEA/US 25 MAR 1996

3 / 18

CTG	GCC	GGC	CTT	TTC	CAG	AAG	AAG	CTG	CTC	CGA	GGT	TGC	ACC	CTC	CTC	1632
Leu	Ala	Gly	Leu	Phe	Gln	Lys	Lys	Leu	Leu	Arg	Gly	Cys	Thr	Leu	Leu	
	530					535					540					
CTC	ACA	GCC	CGG	CCC	CGG	GGC	CGC	CTG	GTC	CAG	AGC	CTG	AGC	AAG	GCC	1680
Leu	Thr	Ala	Arg	Pro	Arg	Gly	Arg	Leu	Val	Gln	Ser	Leu	Ser	Lys	Ala	
545					550					555					560	
GAC	GCC	CTA	TTT	GAG	CTG	TCC	GGC	TTC	TCC	ATG	GAG	CAG	GCC	CAG	GCA	1728
Asp	Ala	Leu	Phe	Glu	Leu	Ser	Gly	Phe	Ser	Met	Glu	Gln	Ala	Gln	Ala	
				565					570					575		
TAC	GTG	ATG	CGC	TAC	TTT	GAG	AGC	TCA	GGG	ATG	ACA	GAG	CAC	CAA	GAC	1776
Tyr	Val	Met	Arg	Tyr	Phe	Glu	Ser	Ser	Gly	Met	Thr	Glu	His	Gln	Asp	
			580					585					590			
AGA	GCC	CTG	ACG	CTC	CTC	CGG	GAC	CGG	CCA	CTT	CTT	CTC	AGT	CAC	AGC	1824
Arg	Ala	Leu	Thr	Leu	Leu	Arg	Asp	Arg	Pro	Leu	Leu	Leu	Ser	His	Ser	
		595					600					605				
CAC	AGC	CCT	ACT	TTG	TGC	CGG	GCA	GTG	TGC	CAG	CTC	TCA	GAG	GCC	CTG	1872
His	Ser	Pro	Thr	Leu	Cys	Arg	Ala	Val	Cys	Gln	Leu	Ser	Glu	Ala	Leu	
	610					615					620					
CTG	GAG	CTT	GGG	GAG	GAC	GCC	AAG	CTG	CCC	TCC	ACG	CTC	ACG	GGA	CTC	1920
Leu	Glu	Leu	Gly	Glu	Asp	Ala	Lys	Leu	Pro	Ser	Thr	Leu	Thr	Gly	Leu	
625					630					635					640	
TAT	GTC	GGC	CTG	CTG	GGC	CGT	GCA	GCC	CTC	GAC	AGC	CCC	CCC	GGG	GCC	1968
Tyr	Val	Gly	Leu	Leu	Gly	Arg	Ala	Ala	Leu	Asp	Ser	Pro	Pro	Gly	Ala	
				645					650					655		
CTG	GCA	GAG	CTG	GCC	AAG	CTG	GCC	TGG	GAG	CTG	GGC	CGC	AGA	CAT	CAA	2016
Leu	Ala	Glu	Leu	Ala	Lys	Leu	Ala	Trp	Glu	Leu	Gly	Arg	Arg	His	Gln	
			660					665					670			
AGT	ACC	CTA	CAG	GAG	GAC	CAG	TTC	CCA	TCC	GCA	GAC	GTG	AGG	ACC	TGG	2064
Ser	Thr	Leu	Gln	Glu	Asp	Gln	Phe	Pro	Ser	Ala	Asp	Val	Arg	Thr	Trp	
		675					680					685				
GCG	ATG	GCC	AAA	GGC	TTA	GTC	CAA	CAC	CCA	CCG	CGG	GCC	GCA	GAG	TCC	2112
Ala	Met	Ala	Lys	Gly	Leu	Val	Gln	His	Pro	Pro	Arg	Ala	Ala	Glu	Ser	
	690					695					700					
GAG	CTG	GCC	TTC	CCC	AGC	TTC	CTC	CTG	CAA	TGC	TTC	CTG	GGG	GCC	CTG	2160
Glu	Leu	Ala	Phe	Pro	Ser	Phe	Leu	Leu	Gln	Cys	Phe	Leu	Gly	Ala	Leu	
705					710					715					720	
TGG	CTG	GCT	CTG	AGT	GGC	GAA	ATC	AAG	GAC	AAG	GAG	CTC	CCG	CAG	TAC	2208
Trp	Leu	Ala	Leu	Ser	Gly	Glu	Ile	Lys	Asp	Lys	Glu	Leu	Pro	Gln	Tyr	
				725					730					735		
CTA	GCA	TTG	ACC	CCA	AGG	AAG	AAG	AGG	CCC	TAT	GAC	AAC	TGG	CTG	GAG	2256
Leu	Ala	Leu	Thr	Pro	Arg	Lys	Lys	Arg	Pro	Tyr	Asp	Asn	Trp	Leu	Glu	
			740					745					750			
GGC	GTG	CCA	CGC	TTT	CTG	GCT	GGG	CTG	ATC	TTC	CAG	CCT	CCC	GCC	CGC	2304
Gly	Val	Pro	Arg	Phe	Leu	Ala	Gly	Leu	Ile	Phe	Gln	Pro	Pro	Ala	Arg	
		755					760					765				
TGC	CTG	GGA	GCC	CTA	CTC	GGG	CCA	TCG	GCG	GCT	GCC	TCG	GTG	GAC	AGG	2352
Cys	Leu	Gly	Ala	Leu	Leu	Gly	Pro	Ser	Ala	Ala	Ala	Ser	Val	Asp	Arg	
	770					775						780				

FIG. 1C

AMENDED SHEET

2197233

PCT/US9 5 / 10 6 9 1
IPEA/US 25 MAR 1996

4 / 18

AAG Lys 785	CAG Gln	AAG Lys	GTG Val	CTT Leu	GCG Ala 790	AGG Arg	TAC Tyr	CTG Leu	AAG Lys	CGG Arg 795	CTG Leu	CAG Gln	CCG Pro	GGG Gly	ACA Thr 800	2400
CTG Leu	CGG Arg	GCG Ala	CGG Arg	CAG Gln 805	CTG Leu	CTT Leu	GAG Glu	CTG Leu	CTG Leu 810	CAC His	TGC Cys	GCC Ala	CAC His	GAG Glu 815	GCC Ala	2448
GAG Glu	GAG Glu	GCT Ala	GGA Gly 820	ATT Ile	TGG Trp	CAG Gln	CAC His	GTG Val 825	GTA Val	CAG Gln	GAG Glu	CTC Leu	CCC Pro 830	GGC Gly	CGC Arg	2496
CTC Leu	TCT Ser	TTT Phe 835	CTG Leu	GGC Gly	ACC Thr	CGC Arg	CTC Leu 840	ACG Thr	CCT Pro	CCT Pro	GAT Asp	GCA Ala 845	CAT His	GTA Val	CTG Leu	2544
GGC Gly	AAG Lys 850	GCC Ala	TTG Leu	GAG Glu	GCG Ala	GCG Ala 855	GGC Gly	CAA Gln	GAC Asp	TTC Phe 860	TCC Ser	CTG Leu	GAC Asp	CTC Leu	CGC Arg	2592
AGC Ser 865	ACT Thr	GGC Gly	ATT Ile	TGC Cys	CCC Pro 870	TCT Ser	GGA Gly	TTG Leu	GGG Gly	AGC Ser 875	CTC Leu	GTG Val	GGA Gly	CTC Leu	AGC Ser 880	2640
TGT Cys	GTC Val	ACC Thr	CGT Arg	TTC Phe 885	AGG Arg	GCT Ala	GCC Ala	TTG Leu	AGC Ser 890	GAC Asp	ACG Thr	GTG Val	GCG Ala	CTG Leu 895	TGG Trp	2688
GAG Glu	TCC Ser	CTG Leu	CGG Arg 900	CAG Gln	CAT His	GGG Gly	GAG Glu	ACC Thr 905	AAG Lys	CTA Leu	CTT Leu	CAG Gln	GCA Ala 910	GCA Ala	GAG Glu	2736
GAG Glu	AAG Lys	TTC Phe 915	ACC Thr	ATC Ile	GAG Glu	CCT Pro	TTC Phe 920	AAA Lys	GCC Ala	AAG Lys	TCC Ser	CTG Leu 925	AAG Lys	GAT Asp	GTG Val	2784
GAA Glu 930	GAC Asp	CTG Leu	GGA Gly	AAG Lys	CTT Leu	GTG Val 935	CAG Gln	ACT Thr	CAG Gln	AGG Arg	ACG Thr 940	AGA Arg	AGT Ser	TCC Ser	TCG Ser	2832
GAA Glu 945	GAC Asp	ACA Thr	GCT Ala	GGG Gly	GAG Glu 950	CTC Leu	CCT Pro	GCT Ala	GTT Val	CGG Arg 955	GAC Asp	CTA Leu	AAG Lys	AAA Lys	CTG Leu 960	2880
GAG Glu	TTT Phe	GCG Ala	CTG Leu	GGC Gly 965	CCT Pro	GTC Val	TCA Ser	GGC Gly	CCC Pro 970	CAG Gln	GCT Ala	TTC Phe	CCC Pro	AAA Lys 975	CTG Leu	2928
GTG Val	CGG Arg	ATC Ile	CTC Leu 980	ACG Thr	GCC Ala	TTT Phe	TCC Ser	TCC Ser 985	CTG Leu	CAG Gln	CAT His	CTG Leu	GAC Asp 990	CTG Leu	GAT Asp	2976
GCG Ala	CTG Leu	AGT Ser 995	GAG Glu	AAC Asn	AAG Lys	ATC Ile	GGG Gly 1000	GAC Asp	GAG Glu	GGT Gly	GTC Val	TCG Ser 1005	CAG Gln	CTC Leu	TCA Ser	3024
GCC Ala	ACC Thr 1010	TTC Phe	CCC Pro	CAG Gln	CTG Leu	AAG Lys 1015	TCC Ser	TTG Leu	GAA Glu	ACC Thr	CTC Leu 1020	AAT Asn	CTG Leu	TCC Ser	CAG Gln	3072
AAC Asn 1025	AAC Asn	ATC Ile	ACT Thr	GAC Asp	CTG Leu 1030	GGT Gly	GCC Ala	TAC Tyr	AAA Lys	CTC Leu 1035	GCC Ala	GAG Glu	GCC Ala	CTG Leu	CCT Pro 1040	3120

FIG. 1D

AMENDED SHEET

2197233

PCT/US9 5 / 10 6 9 1

IPEA/US 25 MAR 1996

5 / 18


TCG	CTC	GCT	GCA	TCC	CTG	CTC	AGG	CTA	AGC	TTG	TAC	AAT	AAC	TGC	ATC	3168
Ser	Leu	Ala	Ala	Ser	Leu	Leu	Arg	Leu	Ser	Leu	Tyr	Asn	Asn	Cys	Ile	
				1045					1050					1055		
TGC	GAC	GTG	GGA	GCC	GAG	AGC	TTG	GCT	CGT	GTG	CTT	CCG	GAC	ATG	GTG	3216
Cys	Asp	Val	Gly	Ala	Glu	Ser	Leu	Ala	Arg	Val	Leu	Pro	Asp	Met	Val	
			1060					1065					1070			
TCC	CTC	CGG	GTG	ATG	GAC	GTC	CAG	TAC	AAC	AAG	TTC	ACG	GCT	GCC	GGG	3264
Ser	Leu	Arg	Val	Met	Asp	Val	Gln	Tyr	Asn	Lys	Phe	Thr	Ala	Ala	Gly	
		1075					1080					1085				
GCC	CAG	CAG	CTC	GCT	GCC	AGC	CTT	CGG	AGG	TGT	CCT	CAT	GTG	GAG	ACG	3312
Ala	Gln	Gln	Leu	Ala	Ala	Ser	Leu	Arg	Arg	Cys	Pro	His	Val	Glu	Thr	
	1090					1095					1100					
CTG	GCG	ATG	TGG	ACG	CCC	ACC	ATC	CCA	TTC	AGT	GTC	CAG	GAA	CAC	CTG	3360
Leu	Ala	Met	Trp	Thr	Pro	Thr	Ile	Pro	Phe	Ser	Val	Gln	Glu	His	Leu	
1105					1110					1115					1120	
CAA	CAA	CAG	GAT	TCA	CGG	ATC	AGC	CTG	AGA	TGA						3393
Gln	Gln	Gln	Asp	Ser	Arg	Ile	Ser	Leu	Arg	*						
				1125				1130								

FIG. 1E

AMENDED SHEET

Determination of the Molecular Biological Function of CIITA

Assay system: The full length CIITA, its 5' and 3' deletion mutants were fused to LexA (an *E. coli* repressor protein) N-Terminal 202 a.a. dimerization/ DNA binding domain, transfected to a yeast transformant bearing a reporter plasmid, pSH34-18, and plated on X-gal containing medium.



Reporter: 8 LexA binding sites, followed by the β -galactosidase gene.
 β -galactosidase + X-gal = BLUE.

CIITA test constructs	Transcription activity (blue/white test)
pEG.CIITA	Blue.
pEG.ciita.N70	Blue.
pEG.ciiTA.N56	Blue.
pEG.ciita.N29	Blue.
pEG.CIITA.C14	White.
pEG.CIITA.C30	White.
pEG.CIITA.C50	White.
pEG.CIITA.C74	White.
pEG.ciita.N22	(Only with domain I,II, and III, no IV) Blue
pEG.ciita.N17	(Only with domain I and II) Blue
pEG.ciita.N12.8	(Only with domain I, the acidic domain) Blue
pEG.ciiTA.N7.6	(Only with partial domain I) Blue

FIG. 2




FIG. 3





FIG. 4

**FIG. 5**




FIG. 6A

anti-DQ(SP.V.L3)




FIG. 6B

2197233

PCT/US95/10691

IPEA/US 25 MAR 1996

12 / 18




FIG. 6C

AMENDED SHEET




FIG. 6D




FIG. 6E


2197233

PCT/US 95 / 10 6 9 1

IPEA/US 25 MAR 1996

15 / 18

NUMBER OF CELLS



RELATIVE LOG FLUORESCENCE INTENSITY

FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D

